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Abstract
Various methods exist for causal inference about the effects of different treatments
from observational studies or randomized trials. A straightforward approach is to fit
a regression model of the outcome as a function of the treatment they received along
with observed patient characteristics. Other methods, such as inverse probability
weighting, work by instead estimating a patient’s probability of receiving treatment
and weighting the outcomes by the inverse of this probability. Doubly Robust estima-
tors use both models and provide unbiased estimates as long as either the probability
of treatment or outcome is correctly modeled. These techniques can be extended to
analyze and compare dynamic treatment regimes, that is, multiple stages of treat-
ment punctuated by decision points concerning what the next treatment should be.
Observational studies and randomized trials represent a cornerstone of public health
research. As they grow and become more complex it is important for the wealth of
statistical methods to grow with them.
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This dissertation is concerned with developing more efficient doubly robust esti-
mators for two-stage dynamic treatment regimes, first without and later, with data
missing at random. First, we develop a new inverse probability of treatment weighted
and doubly robust estimators for analyzing dynamic treatment regimes. Then we
compare these methods to the corresponding existing methods for estimating the
mean outcome of dynamic treatment regimes in a simulation. We utilize the new
doubly robust estimator in the analysis of the STAR*D trial to estimate the mean
outcome of patients on different regimes for the treatment of non-psychotic major
depressive disorder. Finally we propose a modification of the new inverse probability
of treatment weighted and doubly robust estimators in order to account for missing
data.
vii
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1.0 INTRODUCTION
In statistics, we are often interested in finding and estimating causal relationships
between variables. Challenges such as confounding, unobserved data, and lack of
prior knowledge hinder our ability to make accurate and useful causal inference about
the relationships between these variables. Recent history has seen increased interest
in establishing rigorous methodology for the purpose of making causal inference.
1.1 ASSUMPTIONS OF CAUSAL INFERENCE
The first assumption required for causal inference is the consistency assumption
(Robins et. al [2000]), which means that the outcome a patient experiences under a
treatment is in fact, the outcome caused by receiving that treatment. For patients
that do not receive the treatment of interest, that quantity is not observed. Addi-
tionally, causal inference requires that every combination of treatments be possible
for all subjects, this is known as the positivity assumption [Hernan and Robins 2006].
Lastly, it needs the sequential randomization assumption [Robins 1986], which states
that given a subject’s covariate history and prior treatment assignment, the treat-
ment assignment at any given decision point is made independent of all potential
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outcomes. This assumption is known as the no unmeasured confounder assumption.
These assumptions are necessary for unbiased, or at least, consistent, estimation of
treatment effects and the corresponding statistical inference.
1.2 MODELING OUTCOME AND G-COMPUTATION
Consider a trial looking at treatments A and B and comparing their effects on pa-
tient’s outcome Y . For each patient we can only see their outcome given treatment
for one of the two treatments, i.e., for a patient who receives treatment A, we see
that patient’s outcome of Y given A. However we do not observe Y given B, i.e.
patient’s outcome had he or she received treatment B. We refer to this unobserved
potential outcome as a counterfactual outcome.
While counterfactual variables are not always observable they provide avenues to
construct valid estimates and to assess treatment effects from randomized trials or
observational studies. Various methods have been proposed that produce unbiased
and consistent estimates of treatment effects based on the use of counterfactuals. The
standard and most straightforward method is to directly model the outcome given
receiving each treatment. However, the relationship between the observed covariates
and the outcome may be unknown. In the case of non-randomized studies, there may
be unobserved confounders important to the causal relationship between treatment
and outcome.
When comparing treatments within a study, investigators can only observe the
outcome corresponding to the treatment the patient was assigned. This is analogous
to the missing data problem frequently encountered in statistical analysis of biomed-
ical data. All the unobserved potential outcomes can be thought of as missing. One
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common approach to dealing with missing data is to replace the missing values with
approximations based on the observed data. In regression-based imputation, we con-
struct a model of the outcome regressed on treatment and any relevant covariates,
which allows us to estimate the conditional expectation of the outcome given the
treatment the patient did not receive using the resulting model. An unbiased esti-
mate of the mean outcome conditional on receiving a particular treatment is then
constructed by these conditional expectations. More specifically, this estimate of the
mean outcome can be expressed as µˆOR =
1
n
∑n
i=1 m(Xi, βˆ), where m(Xi, β) is the
postulated outcome model for E[Yi|Xi], n is the number of subjects in the sample,
Xi are the covariates of interest, and βˆ is a consistent estimator of β, the parameter
for the outcome model. However, if we misspecify the outcome model m(Xi, β) we
no longer get a unbiased and consistent estimator of the mean outcome under our
treatment of interest.
G-computation is an extension of ordinary least squares regression in settings
where the population is stratified by intermediate responses to treatments. The
G-computation algorithm was developed by Robins [1986] and [1987] in order to
conduct causal inference when patients experience a sustained exposure period. It
has since been used in the analysis of multi-stage studies (see for example, Bembom
and Van der Laan [2007]). In multi-stage treatment settings, the algorithm works by
estimating the distribution of the intermediate outcomes between stages of treatment
and uses weighted averages to obtain estimates of population means.
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1.3 INVERSE PROBABILITY OF TREATMENT WEIGHTING
One approach to causal inference analysis is called inverse probability of treatment
weighting (IPTW). In this approach each observation is weighted with the inverse
of the probability of receiving the treatment the patient received. So a patient who
received treatment A would have a weight of 1/pr(Receiving A). With this method,
a patient counts for herself along with 1/pr(Receiving A) − 1 other patients that
have similar covariate values but for whom we did not see the counterfactual outcome
given treatment A, because they received other treatments. In classical randomized
trials, these probabilities are known and hence it would be straightforward to ap-
ply inverse probability of treatment weighting. In observational studies, however,
treatment assignment probabilities are not known, and need to be estimated from
the data. If we model the probability of receiving treatment based on the observed
covariates the analysis may be flawed in the same way as when modeling the outcome
incorrectly in the previous method. In this case, the accuracy of the estimate will
depend on the relationship between the probability of receiving treatment and the
included covariates. Incorrect specification of this relationship could lead to biased
and/or inefficient inference. Using this method to estimate the mean counterfactual
outcome of the study population receiving A, which we define as Y [A], would result
in the Inverse Probability of Treatment Weighting (IPTW) estimator [Horvitz and
Thompson, 1952]
µˆIPTW =
1
n
n∑
i=1
Z
(A)
i
pi
(A)
i
Yi , (1.1)
4
where Z
(A)
i is the indicator for receiving treatment A, Z
(A)
i = 1, if the patient receives
A, 0, otherwise, pi
(A)
i is the probability of receiving treatment A, and Yi is the outcome
for the ith subject, i = 1, ..., n. We can see that this estimator is unbiased under
correct specification of the treatment model pi
(A)
i by taking its expectation.
E[µˆIPTW ] = E
[
1
n
n∑
i=1
Z
(A)
i
pi
(A)
i
Yi
]
=
1
n
n∑
i=1
E
[
Z
(A)
i
pi
(A)
i
Yi
]
=
1
n
n∑
i=1
E
[
Z
(A)
i
pi
(A)
i
(Yi[A]Z
(A)
i + Yi[¬A](1− Z(A)i ))
]
=
1
n
n∑
i=1
E
[
Z
(A)
i
pi
(A)
i
Yi[A]
]
=
1
n
n∑
i=1
E
[
E
[
Z
(A)
i
pi
(A)
i
Yi[A]
∣∣∣∣Yi[A]
]]
=
1
n
n∑
i=1
E
[
Yi[A]E
[
Z
(A)
i
pi
(A)
i
∣∣∣∣Yi[A]
]]
=
1
n
n∑
i=1
E[Yi[A]] = E[Y [A]] ,
since Pr(Z
(A)
i = 1) = pi
(A)
i under correct treatment model specification.
The past few decades have seen a great expansion of the literature on inverse
probability weighting. Books by van der Laan and Robins [2003] and Tsiatis [2006]
discuss inverse probability weighted augmented estimation, that is, inverse proba-
bility weighted estimators with an additional augmentation term that models the
coarsening mechanism . Robins and Rotnitzky [1992], Robins, Rotnitzky, and Zhao
[1994], and Robins and Rotnitzky [1995] all discuss locally efficient inverse proba-
bility weighted augmented estimation. These estimators are referred to as locally
efficient estimators because they satisfy the conditions that they are both asymptot-
ically normal even when their working models are misspecified and that when they
are correctly specified they have the smallest variance among all inverse probabil-
ity weighted augmented estimators. Furthermore, Rotnitsky, Robins, and Scharfstein
[1998], Robins, Rotnitsky, and Scharfstein [2000], Scharfstein, Rotnitzky, and Robins
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[1999], Scharfstein and Irrizarry [2003], and Birmingham, Rotnitzky, and Fitzmaurice
[2003] all worked on inverse probability weighted augmented estimation in situations
where data are not missing completely at random. Lastly, Robins [1999] discusses
using inverse probability weighting to derive parameter estimates in causal inference
models.
1.4 DOUBLY ROBUST ESTIMATION
There are methods requiring the specification of both outcome and treatment models,
called doubly-robust methods, that allow for unbiased or consistent estimates. This
continues to be true if at least one of the models is correctly specified. Doubly
robust estimation will be the focus of this paper. In the setting described in previous
sections, the doubly robust estimator for mean outcome is
µˆDR =
1
n
n∑
i=1
{
Z
(A)
i
pi(A)(Xi, γˆ)
Yi − Z
(A)
i − pi(A)(Xi, γˆ)
pi(A)(Xi, γˆ)
m(Xi, βˆ)
}
, (1.2)
where pi(A)(Xi, γˆ) and m(Xi, βˆ) are the i
th subject’s estimated probability of treat-
ment and outcome respectively. When the treatment model is true and the coefficient
γ is known then E
[
Z
(A)
i −pi(A)(Xi,γ)
pi(A)(Xi,γ)
∣∣∣∣Xi] = P (Z(A)i =1|Xi)−pi(A)(Xi,γ)pi(A)(Xi,γ) = 0 and E[µˆDR] be-
comes the expected value of the inverse probability of treatment weighted estimator,
and hence is an unbiased estimator of µ. If γ is estimated using a correctly specified
logistic regression model then the estimator is still consistent. Likewise, when the
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outcome model is true and the coefficient β is known we can see
E[µˆDR] = E
[
1
n
n∑
i=1
{
Z
(A)
i
pi(A)(Xi, γˆ)
Yi − Z
(A)
i − pi(A)(Xi, γˆ)
pi(A)(Xi, γˆ)
m(Xi, β)
}]
=
1
n
n∑
i=1
{
E[Yi[A]]E[Z
(A)
i |Yi[A]]
pi(A)(Xi, γˆ)
− E[Z
(A)
i |Yi[A]]− pi(A)(Xi, γˆ)
pi(A)(Xi, γˆ)
E[Yi[A]]
}
=
1
n
n∑
i=1
{
pi(A)(Xi, γˆ)
pi(A)(Xi, γˆ)
E[Yi[A]]
}
=
1
n
n∑
i=1
E[Yi[A]] = E[Y [A]] ,
(1.3)
which is consistent when the βs are correctly estimated.
There has been a wealth of literature published on the subject of doubly robust
estimation since its introduction by Robins [Robins, Am. Statist. Assoc. Sect.
Bayesian Statist. Sci 1999]. Carpenter and Kenward [2006] compare using this
method to the more common approach of multiple imputation. Both Bang and
Robins [2005] and Tsiatis, Davidian, and Cao [2011] utilize doubly robust estimators
in a longitudinal setting and improve its efficiency. Kang and Schafer [2007] compare
various doubly robust, as well as some non-doubly robust, methods in different miss-
ing data scenarios. Rotnitzky, Lei, Sued, and Robins [2012] discuss a doubly robust
estimator derived by solving outcome regression estimating equations. Bai, Tsiatis,
and O’Brien [2013] examine a doubly robust estimator in the survival data setting,
with particular emphasis on stratified sampling schemes.
Cao, Tsiatis, and Davidian [2009] in particular are concerned with the efficient
estimation of the outcome model coefficients in cross-sectional settings. They observe
that even if one correctly specified the treatment model with incorrect specification
of the outcome model the results, while still yielding unbiased estimates, will be
inefficient. They propose an estimating equation for these coefficients that results in
more efficient doubly robust estimates.
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1.5 DYNAMIC TREATMENT REGIMES
Sometimes chronic diseases demand frequent modification of treatments based on
individual responses to the treatment and/or health conditions. Therefore, instead
of caring about which treatment is immediately better a physician may want to
know what course of treatments is best overall. These courses of treatments are
called dynamic treatment regimes. They are rules of treatment choice based on in-
termediate responses and patient characteristics. For example, a dynamic treatment
regime in depression treatment could be ’treat a patient suffering from clinical de-
pression with a selective serotonin re-uptake inhibitor (SSRI), if they respond, keep
them on it, and if not switch them to bupropion (a non-SSRI treatment for clini-
cal depression).’ G-computation, Inverse Probability of Treatment Weighting, and
Doubly Robust estimation all have applications in analyzing and comparing dynamic
treatment regimes.
Dynamic Treatment Regimes can be examined in a clinical trial setting using
sequential, multiple assignment, randomized trial, or SMART, designs (Murphy et
al. 2005). The idea behind these designs is to have multiple stages of treatment
punctuated by randomization at decision points to treatments within certain treat-
ment groups depending on their intermediate responses. For example, continuing
with our clinical depression example, a SMART design would start patients off on an
SSRI like citalopram and at the end of the stage decide if the patient had responded.
Responders could be randomized to a maintenance treatment or simply kept on the
medication that has proven to be effective while non-responders could be random-
ized to a different treatment altogether. A visualization of this design can be seen
in Figure 1.
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Figure 1: SMART Design; Aj = 1st stage Treatment, j=1,2, Bk = 2nd stage Treatment, k=1,2,
9
1.6 THE STAR*D TRIAL
The Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, Trial
was a multistage trial designed to test different regimes of depression treatments.
The trial contained 4,041 patients between the ages of 18 and 75 who had received
a clinical diagnosis of nonpsychotic major depressive disorder under the DSM-IV
checklist. A patient that is considered to respond to treatment will continue taking
that treatment, while those that do not respond are re-randomized to a treatment
within a treatment-grouping of their own choice.
The trial was designed with four (and a half) stages. This study contains a
unique element called Equipoise Stratified Randomization, meaning that patients
were given the option of selecting classes of treatments that they would find ac-
ceptable to be on and then were randomized to one of the treatments within those
groups. This was done in order to boost compliance and decrease drop-out. A pa-
tient with more control over their treatment is thought to be more inclined to follow
that treatment and not leave the study. Everyone received the same treatment in the
first stage, an SSRI called citalopram. Non-responders at each stage were offered a
choice of switching off of their current medication or supplementing it with another
treatment. Non-responders to the second stage who received cognitive therapy or
citalopram supplemented with cognitive therapy that stage were randomized to one
of two medicinal treatments at what investigators called stage 2A. The purpose of
this was to make sure everyone that made it to the third stage received a follow up
medication to citalopram.
Response between stages was defined as either a 50% reduction in QIDS-16 (Quick
Inventory of Depressive Symptomatology) self reported score, which the investigators
call response, or a QIDS-16 score lower than 5, which the investigators call remission,
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at the end of the stage. The overall outcome of interest for investigators was the
HRSD-17 (Hamilton Rating Scale of Depression) score which was collected upon
study exit.
1.7 MOTIVATION
As mentioned there are a number of existing methods to estimate the mean outcomes
of dynamic treatment regimes. The first method we described was G-computation
which directly models outcome and intermediate response. Alternatively, Inverse
Probability of Treatment Weighted (IPTW) estimators utilize the modeled proba-
bility of treatment as weights to account for the missing counterfactual outcomes of
those that did not receive the regime of interest. Finally, Doubly Robust estimators
allow for unbiased estimation of the mean regime outcomes as long as either the
treatment or outcome models are correctly specified.
The existing doubly robust estimator for two-stage dynamic treatment regimes
(Wahed and Tsiatis [2004]) utilizes inverse probability of treatment weighting to
account for patients deviating from second stage treatments, but not first stage
treatments, specified in the regime of interest. This means that the estimator does
not take advantage of all the available data for patients with missing data. This
estimator could be modified to use all the first stage treatment data. However, the
estimator becomes inefficient and biased because the model based correction piece no
longer has expectation zero under correct treatment model specification. This is no
longer the case when the first stage treatment assignment and intermediate response
are independent but independence is an unreasonable assumption to make.
Our goal is to build a new doubly robust estimator that can utilize inverse prob-
11
ability of treatment weighting for both the first and second stages of treatment while
not requiring the same strong independence assumption as the modified existing es-
timator. We expect this estimator to be more efficient and less biased under model
misspecification.
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2.0 EFFICIENT DOUBLY ROBUST ESTIMATION FOR
TWO-STAGE DYNAMIC TREATMENT REGIMES
2.1 INTRODUCTION
When comparing two or more treatments in observational or randomized studies,
for a given patient, investigators can only observe the outcome corresponding to
the treatment received by the patient. Thus, investigators are unable to observe
the potential outcomes that could have been observed had a patient received other
treatments. These potential outcomes a patient could have experienced are often
referred to as counterfactual outcomes [Holland 1986].
While counterfactual variables are not always observable, they provide avenues
to construct valid estimates and to assess treatment effects from randomized trials or
observational studies. Various methods have been proposed that produce unbiased
and consistent estimates of treatment effects based on the use of counterfactuals. The
standard and most straightforward method is to directly model the outcome given
receiving each treatment. However, modeling an outcome may not be straightfor-
ward because of the uncertainty of the relationship between the observed covariates
and the outcome. In the case of non-randomized studies, there may be unobserved
confounders important to the causal relationship between treatment and outcome.
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An alternate approach is called inverse probability of treatment weighting. In this
approach each observation is weighted with the inverse of the probability of receiving
the treatment they received. So a patient who received treatment A1 would have a
weight of 1/pr(ReceivingA1). With this method, a patient counts for herself along
with 1/pr(ReceivingA1)− 1 other patients that have similar covariate values but for
whom we did not see the counterfactual outcome given treatment A1. In classical
randomized trials, these probabilities are known and hence it would be straightfor-
ward to apply inverse probability of treatment weighting. In observational studies,
however, treatment assignment probabilities are not known, and needs to be esti-
mated from the data. If we model the probability of receiving treatment based on
the observed covariates the analysis may be flawed in the same way as when modeling
the outcome incorrectly in the previous method. In this case, the accuracy of the
estimate will depend on the relationship between the probability of receiving treat-
ment and the included covariates. Incorrect specification of this relationship could
lead to biased and/or inefficient inference. However, there are methods requiring the
specification of both outcome and treatment models, called doubly-robust methods,
that allow for unbiased or consistent estimates. This continues to be true if at least
one of the models is correctly specified. Doubly robust estimation will be the focus
of this paper.
There has been a wealth of literature published on the subject of doubly robust
estimation since its introduction by Robins [Robins Am. Statist. Assoc. Sect.
Bayesian Statist. Sci 1999] . Carpenter and Kenward [2006] compare using this
method to the more common approach of multiple imputation. Both Bang and
Robins [2005] and Tsiatis, Davidian, and Cao [2011] utilize doubly robust estimators
in a longitudinal setting and attempt to improve to this method’s efficiency. Kang
and Schafer [2007] compare various doubly robust, as well as some non-doubly robust
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methods in different missing data scenarios. Rotnitzky, Lei, Sued, and Robins [2012]
discuss a doubly robust estimator derived by solving outcome regression estimating
equations. Bai, Tsiatis, and O’Brien [2013] examine a doubly robust estimator in
the survival data setting, with particular emphasis on stratified sampling schemes.
Cao, Tsiatis, and Davidian [2009] in particular are concerned with the efficient
estimation of the outcome model coefficients in cross-sectional settings. They observe
that even if one correctly specified the treatment model with incorrect specification
of the outcome model, the results, while still yielding unbiased estimates, will be
inefficient. They propose an estimating equation for these coefficients that results in
more efficient doubly robust estimates.
Doubly robust estimators discussed above were mostly derived or implemented
for settings where one treatment is compared to another in cross-sectional or lon-
gitudinal settings, but chronic diseases demand frequent modification of treatments
based on individual responses to the treatment and/or health conditions. Therefore,
instead of caring about which treatment is immediately better, a physician may want
to know what course of treatments is best overall. These courses of treatments are
called dynamic treatment regimes (DTRs). They are rules of treatment choice based
on intermediate responses and patient characteristics. For example, a dynamic treat-
ment regime in depression treatment could be ’treat a patient suffering from clinical
depression with a selective serotonin re-uptake inhibitor (SSRI), if they respond keep
them on it, and if not switch them to a drug like bupropion (a non-SSRI treatment
for clinical depression)’.
Comparing dynamic treatment regimes using counterfactual outcomes is gener-
ally more complicated than comparing a single set of treatments. For the latter
it is enough to consider counterfactuals related to a group of treatments, but we
need to think about all possible combinations of initial and follow-up treatments a
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patient could experience in a dynamic treatment regime setting. Dynamic treat-ment 
regimes and related analytical techniques have grown in prominence in the past two 
decades. Murphy [2003] discusses the use of backwards induction and Q-learning as a 
technique for estimating regime outcomes. Bembom and van der Laan [2007] explore 
both inverse probability weighting and g-computation in two stage dynamic 
treatment regime clinical trials. Lunceford, Davidian, and Tsiatis [2002] discuss an 
inverse probability of treatment weighted estimator with a correctional constant 
chosen to minimize variance across a class of estimators they introduce. Zhang, 
Tsiatis, Laber, and Davidian [2013] propose a doubly robust estimator in a dynamic 
treatment regime setting whose efficiency improves through careful choice of an 
augmentation term.
Many well known, large studies aim to compare dynamic treatment regimes. The 
STAR*D trial [Warden et al. 2007], which motivated this research, is a multistage 
clinical trial examining the effects of depression treatments for patients who do not 
respond to SSRIs. The COG study A3891 [Matthay et al. 1999] examines the efficacy 
of chemotherapy followed by bone marrow transplantation versus a second round of 
chemotherapy in children with high-risk neuroblastoma. The REVAMP study 
[Trivedi et al. 2008] is another multistage study concerned with analyzing regimes of 
treatments for chronic depression.
The goal of this paper is to examine doubly robust estimators in a dynamic 
treatment regime setting in order to demonstrate a more efficient construction of the 
two-stage doubly robust estimator.
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2.2 FRAMEWORK
2.2.1 Estimating Causal Treatment Effect
As mentioned in the section above when comparing treatments within a study, in-
vestigators can only observe the outcome corresponding to the treatment the patient
was assigned. This is analogous to the missing data problem frequently encountered
in statistical analysis of biomedical data. All the unobserved potential outcomes can
be thought of as missing. One common approach to dealing with missing data is
to replace the missing values with an approximation based on the observed data.
In regression-based imputation, we construct a model of the outcome regressed on
treatment and any relevant covariates, which allows us to estimate the conditional
expectation of the outcome given the treatment the patient did not receive using the
resulting model. An unbiased estimate of the mean outcome conditional on receiving
a particular treatment is then constructed by these conditional expectations. More
specifically µˆOR =
1
n
∑n
i=1m(Xi, βˆ), where m(Xi, β) is the postulated ordinary least
squares regression model for E[Yi|Xi], n is the number of subjects in the sample, and
βˆ is a consistent estimator of β, the parameter for the outcome model.
An alternative approach would be to impute the missing outcomes using the
outcomes of other, similar patients. Assume a patient received treatment A with
the probability of receiving it pi(A)(Xi, γ), where γ are coefficients that describe the
relationship between the covariates, Xi, and probability of receiving treatment. Then
we can assume that there are 1/pi(A)(Xi, γ) − 1 patients with covariates Xi who
received a different treatment. Therefore, by weighting this patient by 1/pi(A)(Xi, γ)
we can use their outcome µ to account for themselves as well as those 1/pi(A)(Xi, γ)−1
other patients. Using this method to estimate the mean outcome conditional on
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receiving A would result in the Inverse Probability of Treatment Weighting estimator
[Horvitz and Thompson, 1952]
µˆIPTW =
1
n
n∑
i=1
Z
(A)
i
pi(A)(Xi, γˆ)
Yi, (2.1)
where Z
(A)
i is the indicator for receiving treatment A, Z
(A)
i = 1, if the patient receives
A, 0, otherwise, and Yi is the outcome for the i
th subject, i = 1, ..., n. In the above
equation we have also replaced γ by γˆ to indicate that when pi(A) is unknown, it is
estimated from the observed data.
Both of these estimating approaches provide a consistent estimator of the pop-
ulation mean µ given the correct specification of the models involved, outcome and
treatment respectively. Misspecification of these models may result in biased and
inefficient estimates. However, a third approach, doubly robust estimation, allows
for consistent estimation as long as at least one of these models is correctly specified.
This doubly robust estimator is given by
µˆDR =
1
n
n∑
i=1
{
Z
(A)
i
pi(A)(Xi, γˆ)
Yi − Z
(A)
i − pi(A)(Xi, γˆ)
pi(A)(Xi, γˆ)
m(Xi, βˆ)
}
. (2.2)
For a formal argument for why this estimator is consistent when at least one of
the two models is correctly specified, we refer readers to Robins Am. Statist. Assoc.
Sect. Bayesian Statist. Sci [1999].
2.2.2 Causal Inference for Dynamic Treatment Regimes
Now consider the setting of two-stage dynamic treatment regimes where, at decision
points, non-responders receive subsequent follow-up treatments and responders do
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not. Patients will receive up to two levels of treatment. For simplicity, suppose there
are only two first stage treatment options, A1 and A2, and two second stage treatment
options, B1 and B2, for non-responders to the first stage treatments A1 or A2. We
denote intermediate response with Ri = 1 denoting the i
th patient response and
Ri = 0 for their non-response after the first stage of treatment. This setting allows
four dynamic treatment regimes, namely, d(Aj, Bk), j, k = 1, 2, where, for example,
in regime d(A1, B1), a patient initially receives treatment A1 and if non-responsive
is switched to treatment B1. A patient who receives A1, responds, and stays on that
treatment would be considered to be on this regime, and so would someone that does
not respond to A1 and is switched to B1. This creates an interesting problem when
trying to estimate the mean regime outcome in even a randomized controlled trial.
If there were another second stage treatment that a non-responder could switch to,
B2, then for patients who did not respond to A1 and were switched to B2, we do
not observe the outcome under regime d(A1, B1). However, they were part of that
regime up until the second stage of treatment. This is equivalent to outcome data
missing for these patients under regime d(A1, B1) and hence when estimating the
mean outcome under d(A1, B1), we need to account for these missing data. If we
simply take the average outcome of all patients who can be described as following
regime d(A1, B1) then we may get a biased estimate. In this average responders to
A1 will count for more than non-responders because some portion of non-responders
to A1, those assigned to B2, have their outcome missing for our regime of interest.
Let us cast our problem in terms of counterfactual outcomes. Suppose Y [d(Aj, Bk)]
denotes the outcome had the patient been treated with the regime d(Aj, Bk). In
terms of this, the goal is to estimate µ[d(Aj, Bk)] = E{Y [d(Aj, Bk)]}, the mean of a
population who were treated with d(Aj, Bk). However, Yi[d(Aj, Bk)] is not observed
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for every individual, instead we only observe
(Xi, Z
(A)
i , Ri, (1−Ri)Z(B)i , Yi; i = 1, ..., n) , (2.3)
which are respectively the patient’s observed covariates, first stage treatment as-
signment, response to first stage treatment, second stage treatment assignment for
non-responders, and outcome.
The primary assumption required for causal inference is consistency (Robins et.
al [2000]), which in a dynamic treatment regime setting means that the outcome Yi
a patient experiences under a regime d(Aj, Bk) is in fact the counterfactual outcome
Yi[d(Aj, Bk)]. In the case of two treatments at each stage this would be
Yi = Z
(A)
1i [Ri + (1−Ri) ∗ Z(B)1i ] ∗ Yi[d(A1, B1)]
+(1− Z(A)1i )[Ri + (1−Ri) ∗ Z(B)1i ] ∗ Yi[d(A2, B1)]
+Z
(A)
1i [Ri + (1−Ri) ∗ (1− Z(B)1i )] ∗ Yi[d(A1, B2)]
+(1− Z(A)1i )[Ri + (1−Ri) ∗ (1− Z(B)1i )] ∗ Yi[d(A2, B2)] .
(2.4)
As previously mentioned, another assumption necessary for making causal in-
ference is positivity. That is, that the probability of each treatment pathway being
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experienced by a patient is non-zero. Staying in our two treatment per stage example
this would mean
P (Z
(A)
1i = 1) > 0
P (Z
(A)
1i = 0) > 0
P (Ri = 1|Z(A)1i = 1) > 0
P (Ri = 0|Z(A)1i = 1) > 0
P (Ri = 1|Z(A)1i = 0) > 0
P (Ri = 0|Z(A)1i = 0) > 0
P (Z
(B)
1i = 1|Z(A)1i = 1, Ri = 0) > 0
P (Z
(B)
1i = 0|Z(A)1i = 1, Ri = 0) > 0
P (Z
(B)
1i = 1|Z(A)1i = 0, Ri = 0) > 0
P (Z
(B)
1i = 1|Z(A)1i = 0, Ri = 0) > 0 .
(2.5)
The last of our three assumptions is sequential randomization. This assumption
states that the probability of being assigned to a treatment at a decision point
depends only on information observed up to that time. More explicitly,
P (Z
(A)
ji = 1) = P (Z
(A)
ji = 1|Xi)
P (Z
(B)
ki = 1) = P (Z
(B)
ki = 1|Xi, Z(A)ji ).
(2.6)
Bembom and van der Laan [2006] describe a method, known as g-computation,
originally described by Robins [1986], that uses weighted averages, based on response
probability, of conditional intermediate responses to achieve unbiased estimates of
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mean regime outcomes. Specifically, the mean outcome under regime d(Aj, Bk) is
estimated as
µˆG[d(Aj, Bk)] =
1
n
n∑
i=1
{
Rimj(Xi, βˆj) + (1−Ri)mjk(Xi, βˆjk)
}
, (2.7)
where Ri is the i
th patient’s response after the first stage of treatment, Ri = 1, if the
responded to first stage treatment, 0 otherwise, Xi is the i
th patient’s covariates, Xi
is the ith patient’s covariate information, Xi, mj(Xi, βj) is the postulated outcome
model for the conditional expectation of Y for responders given the covariates Xi,
initial treatment Aj. Likewise, mjk(Xi, βjk) is the postulated outcome model for
the conditional expectation of Y for non-responders given the covariates Xi, initial
treatment Aj and second stage treatment Bk. We used hats to indicate that they
are now estimated from the observed data.
The Inverse Probability of Treatment Weighted estimator in a two stage dynamic
treatment regime setting becomes
µˆIPTW [d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji
pi
(A)
j (Xi, γˆj)
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk (Xi, γˆjk)
] }
Yi , (2.8)
where pi
(A)
j (Xi, γˆj) is the modeled probability of receiving treatment Aj based on the
covariates Xi, and pi
(B)
jk (Xi, γˆjk) is the modeled probability of receiving treatment Bk
based on the covariates Xi given non-response to Z
(A)
ji .
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Lastly consider a locally efficient doubly robust estimator for a two-stage dynamic
treatment regime introduced by Wahed and Tsiatis [2004].
µˆDR[d(Aj, Bk)] =
n∑
i=1
Z
(A)
ji
{ [
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk (Xi, γˆjk)
]
Yi
−Z
(B)
ki − pi(B)jk (Xi, γˆjk)
pi
(B)
jk (Xi, γˆjk)
(1−Ri)mjk(Xi, βjk)
}
/
n∑
i=1
Z
(A)
ji .
(2.9)
This estimator is consistent provided at least one of the two models pijk and mjk
are correctly specified. When both models are correctly specified, this estimator is
most efficient, provided βj and βjk are consistently estimated. When we expand this
estimator to include an inverse probability of treatment weighting component for
first stage of treatment, Aj this estimator becomes.
µˆDR[d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji
pˆi
(A)
j
[
Ri +
(1−Ri)Z(B)ki
pˆi
(B)
jk
]
Yi
−Z
(A)
ji − pˆi(A)j
pˆi
(A)
j
Rimj(Xi, βˆj) −
Z
(A)
ji Z
(B)
ki − pˆi(A)j pˆi(B)jk
pˆi
(A)
j pˆi
(B)
jk
(1−Ri)mjk(Xi, βˆjk)
}
,
(2.10)
where mj(Xi, βˆj) and mjk(Xi, βˆjk) are the estimated mean outcomes under treatment
pathways Aj and AjBk respectively.
This estimator is biased and inefficient. It may require that first stage treatment
assignment, Z
(A)
ji is independent of response to that treatment, Ri and violating this
assumption might be to blame for the problem with bias and inefficiency.
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2.3 PROPOSED ESTIMATORS
2.3.1 The Hybrid Inverse Probability of Treatment Weighted Estimator
From the causal inference point of view, we are interested in the outcome if the
study population had received regime d(Aj, Bk). As discussed earlier, this quantity
is Yi[d(Aj, Bk)]. Since all individuals in the sample did not follow this particular
regime, Yi[d(Aj, Bk)] is unobserved for individuals whose treatment is inconsistent
with this regime, and hence missing data techniques can be applied to estimate the
parameter of interest, µ = µYi[d(Aj ,Bk)] = E[Yi[d(Aj, Bk)]]. We first define R
∗
jki, an
indicator that takes the value 1 when the ith individual in the sample is consistent
with the treatment regime d(Aj, Bk), and 0 otherwise. More specifically,
R∗jki = Z
(A)
ji [Ri + (1−Ri) ∗ Z(B)ki ] . (2.11)
The probability of being on the regime d(Aj, Bk), P (R
∗
jki = 1) similarly expressed
as a composite of the probabilities for treatment assignment and intermediate re-
sponse,
P (R∗jki = 1) = P (Z
(A)
ji [Ri + (1−Ri) ∗ Z(B)ki ] = 1) =
P (Z
(A)
ji = 1)[P (Ri = 1|Z(A)ji = 1)+(1− P (Ri = 1|Z(A)ji = 1)) ∗ P (Z(B)ki = 1|Ri = 1, Z(A)ji = 1)] .
If we were to utilize the probability of being on the regime of interest as a unique
weight for each patient we could then define this quantity as
pi
(R∗)
jk (Xi, γˆjk) = pi
(A)
j (Xi, ˆγAj)[pi
(R)
j|Z(A)ji =1
(Xi, γˆR)+(1−pi(R)
j|Z(A)ji =1
(Xi, γˆR))∗pi(B)
k|Z(A)ji =1,R=1
(Xi, ˆγBjk)] .
(2.12)
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The terms pi
(A)
j (Xi, ˆγAj), pi
(B)
k|Z(A)ji =1,R=1
(Xi, ˆγBjk), and pi
(R)
j|Z(A)ji =1
(Xi, γˆR) can in turn
be estimated using logistic regression or similar models. An Inverse Probability of
Treatment Weighted estimator can then be defined as
µˆHIPTW [d(Aj, Bk)] =
1
n
n∑
i=1
{
R∗jki
pˆi
(R∗)
jk (Xi, γˆjk)
}
Yi . (2.13)
We will call this new estimator the Hybrid Inverse Probability of Treatment
Weighted estimator (HIPTW). We call it a hybrid estimator because now we are
modeling both treatment and intermediate response.
2.3.2 The Hybrid Doubly Robust Estimator
The extension of the HIPTW estimator, (2.13), to a doubly robust variant is straight-
forward and analogous to the extension in the single stage setting. We have our
Inverse Probability of Treatment Weighted term and we augment it with a model
based estimation term that only comes in to play when the probability of being on
the regime of interest is incorrectly modeled. We call this the Hybrid Doubly Robust
Estimator and define it as
µˆHDR[d(Aj, Bk)] =
1
n
n∑
i=1
{
R∗jki
pˆi
(R∗)
jk (Xi, γˆjk)
Yi −
R∗jki − pˆi(R
∗)
jk (Xi, γˆjk)
pˆi
(R∗)
jk (Xi, γˆjk)
µˆR
∗
jk (Xi, βˆ)
}
,
(2.14)
where µR
∗
jk (Xi, β) is the mean of the counterfactual outcome corresponding to
being treated with the regime d(Aj, Bk). This new, hybrid two stage doubly ro-
bust estimator has the advantage of being more efficient than the existing two-stage
doubly robust estimator. Additionally it does not require the previously discussed
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unreasonable assumption of first stage treatment assignment is independent of the
outcome of that treatment. Additionally (2.14) can be viewed as the solution to the
estimating equations
ψi(θ) =

ψjiA(Xi, Z
(A)
ji ; γAj)
ψjkiB(Xi, Z
(A)
ji , Z
(B)
ki ; γBjk)
ψiR(Xi, Z
(A)
ji , Ri; γR)
ψiR∗(Xi, R
∗
jki, Yi; β)
ψiHDR(Xi, R
∗
jki, Yi;µHDR)

, (2.15)
where the ψ functions inside the parenthesis are individual estimating equations for
the components of the combined parameter vector,
θ = (γAj , γBjk , γR, β, µHDR) , (2.16)
used in the estimation of µHDR[d(Aj, Bk)]. The first three correspond to logistic
regression models while the fourth is the estimating equation for a linear regression
model for complete cases. More explicitly,
ψjiA(Xi, Z
(A)
ji ; γAj) = Xi
(
Z
(A)
ji −
1
1 + e−X
T
i γAj
)
ψjkiB(Xi, Z
(A)
ji , Z
(B)
ki ; γBjk) = Xi
(
Z
(B)
jki −
1
1 + e−(X
T
i ,Z
(A)
ji )γBjk
)
ψiR(Xi, Z
(A)
ji , Ri; γR) = Xi
(
Ri − 1
1 + e−(X
T
i ,Z
(A)
ji )γR
)
ψiR∗(Xi, R
∗
jki, Yi; β) = R
∗
jki(Yi − µR
∗
jk (Xi, βˆ))
ψiHDR(Xi, R
∗
jki, Yi;µHDR) =
R∗jki
pi
(R∗)
jk (Xi, γjk)
Yi −
R∗jki − pi(R
∗)
jk (Xi, γjk)
pi
(R∗)
jk (Xi, γjk)
µR
∗
jk (Xi, β)− µHDR[d(Aj, Bk)] .
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The final equation is the estimating equation corresponding to the Hybrid Doubly
Robust estimator itself.
Defining the Hybrid Doubly Robust estimator as a solution to the above set of
estimating equations allows us to classify it as an M-estimator. It follows then that
it is asymptotically normal, as well as consistent (Stefanski and Boos [2002]). An
estimator of the variance of the Hybrid Double Robust estimator can be found with
the sandwich estimator of the variance Vn = An(θˆ)
−1Bn(θˆ)An(θˆ)−1
T
/n, where
An(θ) =
1
n
n∑
i=1
∂ψi(θ)
∂θ
=
1
n
n∑
i=1

∂ψjiA
∂γAj
0 0 0 0
0
∂ψjkiB
∂γBjk
0 0 0
0 0
∂ψiR
∂γR
0 0
0 0 0 1 0
∂ψiHDR
∂γAj
∂ψiHDR
∂γBjk
∂ψiHDR
∂γR
∂ψiHDR
∂β
1

and
Bn(θ) =
1
n
n∑
i=1
ψi(θ)ψi(θ)
T ,
where the derivatives found in the matrix An(θ) are defined as
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∂ψjiA
∂γAj
= Xie
−XTi γAj
(
1
1 + e−X
T
i γAj
)2
XTi
∂ψjkiB
∂γBjk
= Xie
−XTi γBjk
(
1
1 + e−X
T
i γBk
)2
XTi
∂ψiR
∂γR
= Xie
−XTi γR
(
1
1 + e−XTi γR
)2
XTi
∂ψiHDR
∂γAj
=
piR∗γAjRi ∗ (Yi − µRjk∗)
(piR∗)2
∂ψiHDR
∂γBjk
=
piR∗γBkRi ∗ (Yi − µRjk∗)
(piR∗)2
∂ψiHDR
∂γR
=
piR∗γRRi ∗ (Yi − µRjk∗)
(piR∗)2
∂ψiHDR
∂β
=
Ri − piR∗
piR∗
piR∗γAj =
∂pi
(R∗)
jk (Xi, γjk)
∂γAj
piR∗γBjk =
∂pi
(R∗)
jk (Xi, γjk)
∂γBjk
piR∗γR =
∂pi
(R∗)
jk (Xi, γjk)
∂γR
.
A similar approach can be used to find an estimator of the variance for the Hybrid
Inverse Probability of Treatment Weighted estimator, the difference being that the
An(θ) and Bn(θ) matrices have smaller dimensions.
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2.4 SIMULATIONS
We based our simulation on the one found in Kang and Schafer (2007) with a few no-
table exceptions. For each subject we generate 8 independent identically distributed
standard normal random variables, which we will call Xa, Xb, Xc, Xd, Xe, Xf , Xg,
and Xh. We assume a two stage design, with non-responders from the first stage
being rerandomized to the second stage. Without loss of generality we will be drop-
ping the j and k subscript, concerning ourselves only with the regime where ZA = 1
and ZB = 1. The treatment probabilities for each stage are
piA = expit(γ10 + γ11 ∗Xe + γ12 ∗Xf + γ13 ∗Xg + γ14 ∗Xh) (2.17)
and
piB = expit(γ20 + γ21 ∗Xe + γ22 ∗Xf + γ23 ∗Xg + γ24 ∗Xh + γ25 ∗ ZA) , (2.18)
where expit is the inverse logit function.
With probability of response to the first stage being defined as
piR ∼ BERNOULLI(τ0 + τ1 ∗ ZA) . (2.19)
The outcome variable, Y , is then written as
Y = β0 + β1 ∗ ZA + β2 ∗ ZB + β3 ∗Xa + β4 ∗Xb
+β5 ∗Xc + β6 ∗Xd + β7 ∗R + β8 ∗ ZA ∗ ZB + e ,
(2.20)
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where e ∼ N(0, 1) are normally distributed error terms. Now the observed co-
variates are
X1 = e
Xa
2
X2 =
Xb
1 + eXa
+ 10
X3 = (
Xa ×Xc
25
+ .6)3
X4 = (Xb +Xd + 20)
2
X5 = e
Xe
2
X6 =
Xf
1 + eXe
+ 10
X7 = (
Xe ×Xg
25
+ .6)3
X8 = (Xf +Xh + 20)
2 .
(2.21)
Since it would be unreasonably difficult for any investigator to correctly identify the
correct relationship between observed covariates and either outcome or treatment we
assume the following incorrect models could be specified:
Y = ξˆ10 + ξˆ11 ∗X1 + ξˆ12 ∗X2 + ξˆ13 ∗X3 + ξˆ14 ∗X4 + ξˆ15 ∗ ZA , (2.22)
which is the outcome model for those who did respond to the initial treatment.
Y = ξˆ20+ξˆ21∗X1+ξˆ22∗X2+ξˆ23∗X3+ξˆ24∗X4+ξˆ25∗ZA+ξˆ26∗ZB+ξˆ27∗ZA∗ZB , (2.23)
which is the outcome model for those who did not respond to the initial treatment
and were rerandomized to a second stage treatment.
ZA ∼ ηˆ11 ∗X5 + ηˆ12 ∗X6 + ηˆ13 ∗X7 + ηˆ14 ∗X8
and
ZB ∼ ηˆ21 ∗X5 + ηˆ22 ∗X6 + ηˆ23 ∗X7 + ηˆ24 ∗X8 + ηˆ25 ∗ ZA ,
(2.24)
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which are logistic regressions of the treatment assignments on the covariates with ξ
and η as their estimated coefficients.
We perform a series of 10,000 Monte Carlo simulations in order to asses the va-
lidity of our estimator under circumstances where one or both of the types of models
are misspecified. For the first simulation the true value of the estimand, the mean
counterfactual outcome µ{Y [d(A,B)]} = E{Y [d(A,B)]} = 142.398,
β = (110, 24.7, 13.7, 124.7, 73.7, 23.7, 50.7, 20.2,−10.7), τ = (.2,−.7), and
γ = (γ10, γ11, γ12, γ13, γ14, γ20, γ21, γ22, γ23, γ24, γ25) = (−.3,−.75,−.2, .5, 1, .2,−.2,−.3, .4,−.5,−.7).
In the second simulation, created to more closely mimic the STAR*D data, the true
value of the estimand is µ{Y [d(A,B)]} = E{Y [d(A,B)]} = 7.39546,
β = (−0.932,−0.137, 1.51, 0.045, 0.313, 0, 0, 5.09,−0.951), τ = (−0.559, 0.711), and
γ = (0,−0.457,−0.135, 0, 0, 0,−0.074,−0.041, 0, 0, .500). We also varied sample size
in both simulations, running the simulation at n = 200 and n = 500 for the first
simulation and n=200 for the second, as well as examining the estimators under
both standard normal and t-distribution error structures in the first simulation and
standard normal error structures in the second.
2.4.1 Simulation Results
In Table 1 we see the results for running the simulation at n = 200 with standard
normal errors. When both treatment and outcome models are correct, all the estima-
tors except for the existing doubly robust estimator are approximately unbiased with
relative biases below 3%. For the existing doubly robust estimator, this bias is 4.2%
vesus a bias of -2.6% for the Hybrid Doubly Robust estimator. The G-Computation
and IPTW estimators expectedly have the smaller biases compared to others, 0.4
and -0.5% respectively, while the Hybrid IPTW estimator has a larger bias at -2.9%.
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Table 1: n=200, Standard Normal Errors, µ{Y [d(A,B)]} = 142.398
Treatment Model Method Bias MCSE MSE
Outcome Model (%)
Correct
Correct
G− Comp 0.4 21.4 478
IPTW -0.5 38.1 1490
DR 4.2 20.2 463
HIPTW -2.9 31.5 1040
HDR -2.6 11.2 150
Incorrect
Correct
G− Comp 0.4 21.4 478
IPTW 4.4 63.6 4140
DR 0.9 20.1 423
HIPTW 2.1 66.6 4510
HDR -2.5 11.3 151
Correct
Incorrect
G− Comp 0.4 21.4 478
IPTW 0.5 38.1 1490
DR 4.2 20.2 463
HIPTW -2.9 31.5 1040
HDR -1.6 13.7 207
Incorrect
Incorrect
G− Comp 0.4 21.4 478
IPTW 4.4 63.6 4140
DR 3.3 36.9 1420
HIPTW 2.1 66.6 4510
HDR -1.6 17.1 315
G − Comp = G-Computation, IPTW = Inverse Probability of Treatment Weighted Estimator,
DR = Doubly Robust Estimator, HIPTW = Hybrid Inverse Probability of Treatment Weighted
Estimator, HDR = Hybrid Doubly Robust Estimator
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Table 2: n=500, Standard Normal Errors, µ{Y [d(A,B)]} = 142.398
Treatment Model Method Bias MCSE MSE
Outcome Model (%)
Correct
Correct
G− Comp 0.7 13.3 191
IPTW 0.6 24.6 628.0
DR 3.0 12.5 186.0
HIPTW -2.4 19.2 399.0
HDR -2.4 7.1 68.1
Incorrect
Correct
G− Comp 0.7 13.3 191
IPTW 8.8 144.0 21100.0
DR -1.9 15.7 270.0
HIPTW 6.1 156.0 24600.0
HDR -2.3 8.1 83.5
Correct
Incorrect
G− Comp 0.7 13.30 191
IPTW 0.6 24.6 628.0
DR 3.0 12.5 186.0
HIPTW -2.4 19.2 399.0
HDR -1.9 8.5 88.8
Incorrect
Incorrect
G− Comp 0.7 13.3 191
IPTW 8.8 144.0 21100
DR -0.5 17.4 321
HIPTW 6.1 156.0 24600
HDR -1.5 33.9 1180
G − Comp = G-Computation, IPTW = Inverse Probability of Treatment Weighted Estimator,
DR = Doubly Robust Estimator, HIPTW = Hybrid Inverse Probability of Treatment Weighted
Estimator, HDR = Hybrid Doubly Robust Estimator
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Table 3: n=200, t-Distribution with df=5 Errors, µ{Y [d(A,B)]} = 142.398
Treatment Model Method Bias MCSE MSE
Outcome Model (%)
Correct
Correct
G− Comp 0.5 21.4 479
IPTW -0.1 46.4 2200
DR 4.6 37.6 1500
HIPTW -3.0 31.5 1040
HDR -2.4 11.1 147
Incorrect
Correct
G− Comp 0.5 21.4 479
IPTW 5.3 136.0 18600
DR 0.6 37.2 1420
HIPTW 2.5 75.5 5780
HDR -2.3 11.8 163
Correct
Incorrect
G− Comp 0.5 21.4 479
IPTW -0.1 46.4 2200
DR 4.6 37.6 1500
HIPTW -3.0 31.5 1040
HDR -1.5 13.7 205
Incorrect
Incorrect
G− Comp 0.5 21.4 479
IPTW 5.3 136.0 18600
DR 3.7 50.9 2670
HIPTW 2.5 75.5 5780
HDR -1.4 24.1 607
G − Comp = G-Computation, IPTW = Inverse Probability of Treatment Weighted Estimator,
DR = Doubly Robust Estimator, HIPTW = Hybrid Inverse Probability of Treatment Weighted
Estimator, HDR = Hybrid Doubly Robust Estimator
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Table 4: n=500, t-Distribution with df=5 Errors, µ{Y [d(A,B)]} = 142.398
Treatment Model Method Bias MCSE MSE
Outcome Model (%)
Correct
Correct
G− Comp 0.7 13.4 194
IPTW 0.311 23.5 576.0
DR 3.0 12.4 184.0
HIPTW -2.6 18.8 385.0
HDR -2.4 7.0 67.9
Incorrect
Correct
G− Comp 0.7 13.4 194
IPTW -9.5 2390.0 5690000
DR -1.7 15.3 256
HIPTW -17.1 3050.0 9280000
HDR -2.9 86.7 7610
Correct
Incorrect
G− Comp 0.7 13.4 194
IPTW 0.3 23.5 576.0
DR 3.0 12.4 184.0
HIPTW -2.6 18.8 385.0
HDR -2.0 8.5 89.6
Incorrect
Incorrect
G− Comp 0.7 13.4 194
IPTW -9.5 2390.0 5690000
DR -0.3 16.8 300
HIPTW -17.1 3050.0 9280000
HDR -6.1 620.0 385000
G − Comp = G-Computation, IPTW = Inverse Probability of Treatment Weighted Estimator,
DR = Doubly Robust Estimator, HIPTW = Hybrid Inverse Probability of Treatment Weighted
Estimator, HDR = Hybrid Doubly Robust Estimator
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Table 5: With X8, n=200, Standard Normal Errors, Y [d(A,B)] = 142.398
Treatment Model Method Sandwich Est. SE MCSE Coverage (%)
Outcome Model
Correct HDR 11.1 11.2 93.7
Correct
Incorrect HDR 128.1 11.3 99.8
Correct
Correct HDR 13.5 13.7 95.8
Incorrect
Incorrect HDR 610.2 17.1 100
Incorrect
HDR = Hybrid Doubly Robust Estimator
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Table 6: With X8, n=500, Standard Normal Errors, Y [d(A,B)] = 142.398
Treatment Model Method Sandwich Est. SE MCSE Coverage (%)
Outcome Model
Correct HDR 7.0 7.1 92.0
Correct
Incorrect HDR 63.5 8.1 99.8
Correct
Correct HDR 8.5 8.5 93.1
Incorrect
Incorrect HDR 310.0 33.9 100
Incorrect
HDR = Hybrid Doubly Robust Estimator
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Table 7: Without X8, n=200, Standard Normal Errors, Y [d(A,B)] = 142.398
Treatment Model Method Sandwich Est. SE MCSE Coverage (%)
Outcome Model
Correct HDR 11.1 11.2 93.7
Correct
Incorrect HDR 12.0 11.2 95.5
Correct
Correct HDR 13.5 13.7 95.8
Incorrect
Incorrect HDR 20.5 14.2 98.0
Incorrect
HDR = Hybrid Doubly Robust Estimator
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Table 8: Without X8, n=500, Standard Normal Errors, Y [d(A,B)] = 142.398
Treatment Model Method Sandwich Est. SE MCSE Coverage (%)
Outcome Model
Correct HDR 7.0 7.1 92.5
Correct
Incorrect HDR 7.4 8.1 93.4
Correct
Correct HDR 8.5 8.5 93.1
Incorrect
Incorrect HDR 10.8 9.19 96.9
Incorrect
HDR = Hybrid Doubly Robust Estimator
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Table 9: n=2000, Standard Normal Errors, µ{Y [d(A,B)]} = 142.398
Treatment Model Method Bias MCSE MSE
Outcome Model
Correct
Correct
G− Comp -0.002 0.135 0.153
IPTW 0.007 0.146 0.167
DR 9.78 0.116 0.653
HIPTW -8.00 0.158 0.533
HDR -8.04 0.150 0.526
Incorrect
Correct
G− Comp -0.002 0.135 0.153
IPTW -0.06 0.158 0.183
DR 8.10 0.157 0.541
HIPTW -6.56 0.191 0.463
HDR -8.04 0.161 0.540
Correct
Incorrect
G− Comp -0.002 0.135 0.153
IPTW 0.007 0.146 0.167
DR 9.78 0.116 0.653
HIPTW -8.00 0.158 0.533
HDR -8.03 0.151 0.527
Incorrect
Incorrect
G− Comp -0.00213 0.135 0.153
IPTW -0.006 0.158 0.183
DR 8.10 0.157 0.540
HIPTW -6.56 0.191 0.463
HDR -8.04 0.161 0.541
G − Comp = G-Computation, IPTW = Inverse Probability of Treatment Weighted Estimator,
DR = Doubly Robust Estimator, HIPTW = Hybrid Inverse Probability of Treatment Weighted
Estimator, HDR = Hybrid Doubly Robust Estimator
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Table 10: n=2000, Standard Normal Errors, Y [d(A,B)] = 7.39546
Treatment Model Method Sandwich Est. SE MCSE Coverage (%)
Outcome Model
Correct HDR 0.146 0.150 85.0
Correct
Incorrect HDR 0.138 0.161 80.1
Correct
Correct HDR 0.146 0.151 83.8
Incorrect
Incorrect HDR 0.156 0.161 85.8
Incorrect
HDR = Hybrid Doubly Robust Estimator
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Likewise, all of the estimators except for the IPTW and Hybrid IPTW have Monte
Carlo standard errors under 30. The existing IPTW estimator has a MCSE of 38.1
compared to the Hybrid IPTW’s MCSE of 31.5. The Hybrid Doubly Robust esti-
mator performs the best with a MCSE of 11.2 versus 20.2 for the existing Doubly
Robust estimator and 21.4 for the G-Computation estimator. As in the case of the
MCSE, the MSE of the existing IPTW and Hybrid IPTW estimators is much larger
than the other estimators, at 1490 and 1040 respectively, while the other estimators
have an MSE under 500. The Hybrid Doubly Robust estimator, with an MSE of 150,
also outperforms the existing Doubly Robust and G-Computation estimators, whose
MSEs are 463 and 478, respectively. When only the outcome models are incorrectly
specified the estimators maintain their relationships to one another in terms of bias,
Monte Carlo standard error, and mean squared error.
However, we see some of these relationships change when only the treatment
models are incorrectly specified. The existing Doubly Robust estimator now has a
lower bias than the Hybrid Doubly Robust estimator at 0.9% and -2.5% respectively.
The Hybrid IPTW estimator also now has lower bias, at 2.1%, than both the Hybrid
Doubly Robust estimator and the existing IPTW estimator, which has a bias of 4.4%.
Also, now the relationship between the existing IPTW and Hybrid IPTW estimators
is reversed in terms of both MCSE and MSE. The existing IPTW estimator now
has a lower MCSE and MSE, 63.6 and 4510 respectively. While the Hybrid IPTW
estimator has an MCSE of 66.6 and an MSE of 4510. The other estimators keep
their relationships to one another and maintain Monte Carlo standard errors under
30 and mean squared errors under 500.
When both treatment and outcome models are incorrectly specified the relation-
ships between these estimators change slightly from when only the treatment models
were incorrectly specified. In terms of relative bias the existing IPTW and Doubly
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Robust estimators are now both over 3% with 4.4% and 3.1% respectively. The
Hybrid IPTW estimator is now less biased, at 2.1%, than both the existing IPTW
and Doubly Robust estimators. Additionally the existing Doubly Robust estimator
now has an MCSE over 30, at 36.9, and an MSE over 500, at 1420. This means
that the G-Computation estimator now has a lower MSE, at 478, than the existing
Doubly Robust estimator in addition to the IPTW and Hybrid IPTW estimators.
Now only the Hybrid Doubly Robust estimator has a lower MSE, at 315, than the
G-Computation estimator.
In summary, Table 1 shows us some interesting dynamics between the estimators.
When the treatment models are correctly specified, the regular IPTW estimator is
less biased, has a higher Monte Carlo standard error, and a lower MSE than the
new Hybrid IPTW estimator. This is result, however is reversed when the treatment
model is misspecified. The Hybrid Doubly Robust estimator has the lowest Monte
Carlo standard errors and MSE of any estimator regardless of model misspecification
at this sample size. The regular Doubly Robust estimator has lower bias than the
Hybrid Doubly Robust estimator only when the treatment models are incorrectly
specified and the outcome models are not. G-computation has the lowest bias of any
of the methods but it is important to note that only the outcome models for pathway
endpoints are incorrectly specified, not the models for intermediate response. G-
computation and regular IPTW produce estimators with biases of similar magnitudes
when both treatment and outcome models are correctly specified.
Table 2, where now n = 500 with standard normal errors has similar results to
Table 1 with a few notable exemptions. Now when both the oucome and treatment
models are incorrectly specified the Hybrid Doubly Robust estimator performs worse
than the regular Doubly Robust estimator in terms of bias (-1.5% versus -.05%),
MCSE (33.9 versus 17.4), and MSE (1180 vs 321).
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Table 3 are the results for running the simulation at n = 200 with error terms
being generated from a student’s t-distribution with 5 degrees of freedom. It is
similar to Table 1 with the exception that now when both outcome and treatment
models are incorrectly specified the Hybrid Doubly Robust estimator is inferior to
the G-computation estimator in terms of MCSE (24.1 versus 21.4) and MSE (607
versus 479).
Table 4 produces interesting results. One of the Monte Carlo simulation runs con-
tained a single observation that, under the incorrectly specified model for estimating
probability of receiving treatment A, received a very small probability of receiving
its actual treatment assignment. This in turn caused that observation to receive a
abnormally high weight. The estimators utilizing inverse probability weighting for
this run suffered from increased estimated biases, Monte Carlo standard errors, and
MSEs as a result of this single run.
Table 5 shows a comparison between the stadard error computed using the sand-
wich estimator of the variance and the Monte Carlo standard error at n = 200. The
Table shows that when the treatment models are correctly specified the sandwich
estimator produces accurate, if slightly under estimated, estimators of the standard
error. When both models are correctly specified the sandwich estimator is 11.1 versus
the MCSE of 11.2 and when only the outcome is incorrectly specified the sandwich es-
timator is 13.5 versus the MCSE of 13.7. When the treatment models are incorrectly
specified then the sandwich estimator of the variance appears not to be very accurate
at all. With only the treatment models incorrectly specified the sandwich estimator
is 128.1 versus the MCSE of 11.3. When both models are incorrectly specified the
sandwich estimator becomes even less accurate with 610.2 versus the MCSE of 17.1.
Table 6 corroborates this by showing similar discrepancies under treatment model
misspecification at n = 500. The coverage at both sample sizes are provides slightly
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suboptimal coverage when the treatment model is correctly specified and over cov-
erage when incorrect. A close examination of what was happening in the simulation
revealed that the elements of the matrix An(θˆ) corresponding to X8, a variable in
the misspecified treatment models, were abnormally large and were contributing the
majority of the estimated error.
Tables 7 and 8 show the results of the simulation with X8 removed from the
misspecified treatment models at n = 200 and n = 500 respectively. When the treat-
ment models are incorrectly specified and the outcome models are not the sandwich
estimator is accurate, with it being a slight over estimate at n = 200, with a value of
12.0 versus the MCSE of 11.2, and a slight under estimate at n = 500, with a value
of 7.4 versus the MCSE of 8.1. Both Tables show that when both the treatment
models and the outcome models are incorrectly specified the standard error derived
from the sandwich estimator of the variance are slight over estimates of the standard
error. This over estimate is higher at the smaller sample size with a sandwich esti-
mator value of 20.5 versus the MCSE of 14.2. At n = 500 this over estimated value
is lower at 10.8 versus 9.19. At n = 200 the coverage probabilities when at least one
model is correctly specified are close to 95% while at n = 200 they become slightly
suboptimal. When both models are misspecified the coverage at both sample sizes
are larger then 95%.
Finally, in Tables 9 and 10 we see that in the second simulation the HDR esti-
mator performs worse then the other estimators. There is an increase in bias, likely
caused by the smaller ratio of intercept to treatment effect coefficients in the outcome
model. The higher effect of first stage treatment on outcome reveals a problem with
the Hybrid estimators in such a scenario. The lower coverage for HDR in the the
second simulation is due to the higher bias of the estimator.
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2.5 CONCLUSION
At low sample sizes, a number of encouraging results start to appear. First, the new 
hybrid estimators are more efficient than their non-hybrid counterparts. Also, at low 
sample sizes, and with the exception of when only the outcome is correctly specified, 
the new Hybrid Double Robust estimator is both less biased and has a smaller 
mean squared error then the classic doubly robust estimator. The Hybrid Inverse 
Probability of Treatment Weighted estimator is more biased than its non-hybrid 
counterpart under correct model specification but considerably less biased when the 
treatment model is incorrectly specified. The hybrid inverse probability weighted 
estimator has a lower mean squared than its non-hybrid counterpart regardless of 
correct treatment model specification.
At larger sample sizes, the Hybrid Double Robust estimator is less biased, more 
efficient, and has a lower mean squared error than the non-Hybrid Double Robust 
estimator but only when the treatment model is correctly specified. Under correct 
treatment model specification, the Hybrid Inverse Probability of Treatment Weighted 
estimator is more efficient and has a lower mean squared standard error than its coun-
terpart but does not maintain that advantage under treatment model misspecification 
at higher sample sizes.
With non-standard error terms generated using the student’s t-distribution with 
5 degrees of freedom, all of the advantages of the hybrid estimators at low sam-
ple sizes are still present but at larger sample sizes the hybrid methods faults are 
magnified in the case of treatment model misspecification. This is the result of 
the t-distribution being very tail heavy and this creates incorrect weights when the 
estimated treatment probability is poorly constructed and lead to very unstable esti-
mates. One solution to this would be to truncate weights if, after modeling treatment 
assignment probabilities, probabilities were found that were very high or very low.
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The sandwich estimator of the variance appears to be unbiased but unstable when
the treatment model is misspecified. In particular the presence of the variable X8 in
the treatment models causes a large amount of bias. Removing the variable removes
the bias.
However, when, in the case of our second simulation, the intercept is close in
magnitude to the effect size of the treatments, the estimator becomes biased.
2.6 THE STAR*D TRIAL
The Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, Trial was
a 7 year multistage trial designed to test different regimes of depression treatments.
The trial contained 4,041 patients between the ages of 18 and 75 who had received a
clinical diagnosis of nonpsychotic major depressive disorder under the DSM-IV
checklist. A patient that is considered to respond to treatment will continue taking
that treatment, while those that do not respond are re-randomized to a treatment
within a treatment-grouping of their own choice. Although the trial was designed with
four and a half stages, we will only be looking at the 2nd and 3rd stage treat-ments.
This is because everyone received the same treatment in the first stage, an SSRI called
citalopram, and if we included the 4th stage into our analysis our regime sample sizes
would be too small to make any reasonable inferences. We will also be excluding
patients that received cognitive therapy in the second stage. They have the possibility
of being assigned to an extra half stage, which would make analysis difficult in ways
similar to if we had included the 4th stage in our analysis. So our analysis will
center on comparing regimes for follow up medications for patients with depression
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Figure 2: STAR*D Stages of Treatment.
Warden et al. [2007]
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Table 11: STAR*D Dynamic Treatment Regimes
Regime n Mean (QIDS-16) 95% Confidence Interval
d(BUP,MIRT) 95 7.4 (7.3, 7.5)
d(BUP,NTP) 93 7.8 (7.7, 7.9)
d(BUP,BUP+LI) 85 7.7 (7.6, 7.9)
d(BUP,BUP+THY) 73 6.2 (5.9, 6.5)
d(SER,MIRT) 117 7.4 (7.4, 7.5)
d(SER,NTP) 108 6.7 (6.6, 6.8)
d(SER,SER+LI) 97 6.3 (6.2, 6.4)
d(SER,SER+THY) 96 6.1 (6.0, 6.2)
d(VEN,MIRT) 120 7.4 (7.3, 7.5)
d(VEN,NTP) 119 6.7 (6.6, 6.7)
d(VEN,VEN+LI) 108 6.9 (6.8, 7.0)
d(VEN,VEN+THY) 113 6.2 (6.2, 6.3)
d(CIT+BUP,MIRT) 157 6.4 (6.3, 6.5)
d(CIT+BUP,NTP) 163 6.7 (6.7, 6.8)
d(CIT+BUP,CIT+LI) 161 6.5 (6.4, 6.6)
d(CIT+BUP,CIT+THY) 167 5.9 (5.9, 6.0)
d(CIT+BUS,MIRT) 153 7.7 (7.7, 7.8)
d(CIT+BUS,NTP) 160 7.2 (7.1, 7.3)
d(CIT+BUS,CIT+LI) 145 8.1 (8.0, 8.2)
d(CIT+BUS,CIT+THY) 151 6.7 (6.7, 6.8)
49
depression that are non-responsive to SSRIs. For that reason stage 2 and 3 treat-
ments will be henceforth be represented by 1st and 2nd stage notations under our 
conventions. So a response to stage 2 would be indicated by R1, the outcome model 
for stage 3 would be denoted mjk, and so on. A visual representation of the trial can be 
seen in figure 2.
Response is defined as either a 50% reduction in QIDS-16 (Quick Inventory of De-
pressive Symptomatology) self reported score, which the investigators call response, 
or a QIDS-16 score lower than 5, which the investigators call remission, at the end of 
the stage. The QIDS-16 score is also the outcome measure we will be looking at in 
our analysis, rather than the HRSD-17 (Hamilton Rating Scale of Depression) score 
which the original investigators used. This is because QIDS-16 was recorded at every 
visit while HRSD-17 was recorded upon exiting or finishing the trial, QIDS-16 scores 
would be available for more patients than the HRSD-17 was for. It should be noted 
that the QIDS-16 remission rates were generally higher than HRSD-17 rates, mainly 
because the study counted not having an exit HRSD-17 score as non-response. We 
will also differ from the study in that we will keep our overall outcome continuous 
rather than transform it to being binary. Transforming a continuous measure into 
a binary one is always accompanied by a loss of information. As with the original 
analysis by the investigators we assume, one could argue wrongly, that dropout from 
the study represents non-response and we use last observation carried forward as the 
final outcome.
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The treatment probabilities for each stage were estimated using logistic regression
modeling probability of receiving treatment of interest on the covariates Burden
of Side Effects Rating (Wisniewski 2006) and change in QIDS-16 score that were
measured during the previous stage. The outcomes were linearly modeled using
our previously described β estimating technique with the covariates being age and
QIDS-16 score at the beginning of stage 2.
Applying our new, more efficient doubly robust estimator to the data yields the
results seen in the Tables and Figures below.
By this analysis, the best follow up treatment if citalopram is not effective is found
to be either sertraline or citalopram combined with bupropion sustained release.
Additionally the best regimes involve the third stage treatment of supplementing
the second stage treatment with triiodothyronine. The best overall regime appears
to be ’If non-response to citalopram augment it with bupropion sustained release and
if non-response to that switch to supplementing citalopram with triiodothyronine.’
2.7 DISCUSSION
In this paper, we have introduced a new way of constructing estimators for two-stage
dynamic treatment regimes, creating both a Hybrid Inverse Probability of Treatment
Weighted estimator and a Hybrid Double Robust estimator. Through simulations
we have shown that these estimators generally perform better than their non-hybrid
counterparts by the metrics of bias, standard error, and mean standard error. Finally,
we have applied the new Hybrid Double Robust estimator to the STAR*D data set
in order to estimate the treatment effects of two stage dynamic treatment regimes for
patients with non-psychotic major depressive disorder who do not respond to SSRIs.
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One limitation of the methodology described in this chapter is that it discards
data for whom the outcome data or treatment data are missing. This may result
in bias, or efficiency loss as patients in trials can dropout for various reasons. Next
chapter we introduce an estimator that, in addition to dealing with the missing
data problem of not seeing the outcome under the regime of interest for all patients,
addresses missing data due to dropout.
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Figure 3: Forest Plot of STAR*D Dynamic Treatment Regimes
QIDS-16 Score of 5 = Remission; BUP - bupropion sustained release; BUS - buspirone; CIT - citalopram; Li - lithium; MIRT -
mirtazapine; NTP - nortriptyline; SER - sertraline; THY - triiodothyronine
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3.0 EFFICIENT INVERSE PROBABILITY OF TREATMENT
WEIGHTING ESTIMATION FOR TWO-STAGE DYNAMIC
TREATMENT REGIMES WITH DROP-OUT
3.1 INTRODUCTION
Drop-out is a common phenomenon in clinical studies. Patients will leave them for a
variety of reasons and both legal and ethical constraints prevent investigators from
collecting data from them after they dropout. Several issues that come up over the
course of study that takes place over a long period may cause a lose of patients.
Some reasons, such as a patient moving out of the area, are unrelated to the study
itself and thus missing data stemming from them may be ignored. This type of
missingness is typically called missing completely at random and analyses deleting
missing data records remain unbiased. We call these complete case analyses. Other
reasons, such as a patient leaving a study due to a lack of treatment efficacy or harsh
side effects are most likely related to the treatments being administered within the
study and thus ignoring this instance of missing data could result in an inaccurate
analysis of the data. Statistically speaking, if the probability of a data point being
observed given other observed data and missing data only depends on observed data,
this type of missing data is called missing at random. This means the mechanism
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causing dropout in such a scenario is observed. There are many methods designed
to deal with data that are missing at random. When the probability of a data point
being observed depends on the data that are unobserved, the mechanism is defined
as missing not at random. Here we do not fully observe the mechanism of how the
data are missing, such data is difficult to work with. This framework for missing
data was first proposed by Rubin [1976]. Investigators spend a lot of time and effort
on working with missing data in order to produce accurate and efficient results.
Studies comparing dynamic treatment regimes typically experience drop-out for
a range of reasons. First, since the studies examine regimes of treatment, they can
extend well past the length of a typical clinical trial. In such circumstances it is
not unreasonable to assume that patients will experience a assortment of life events,
such as moving, child birth, or even death, that could cause them to leave the study
unexpectedly and for reasons mostly unrelated to the study itself. Second, if the
dynamic treatment regimes are designed to find an efficacious treatment for a chronic
disease, such as depression, then patients may become discouraged with the receipt
of ineffective treatment and leave the study. Likewise dynamic treatment regimes
for chronic illnesses such as cancer can include treatments with severe negative side
effects that can cause a patient to leave the study. Thus it is important not to
simply discard data on patients who fall into the second category, doing so can lead
to biased and inefficient estimation of population parameters. From here on we will
be assuming that all missing data are missing at random.
A common approach to missing data is to use observed data to impute the miss-
ing observations. Unconditional mean imputation, described by Little and Ruben
[2002], uses the mean value of a variable across the observed data in place of any
missing observation’s value for that variable. Conditional mean imputation, defined
by Buck[1960] also known as regression imputation or Buck’s method, models a vari-
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able, not seen for every observation, on a set of variables observed for all subjects.
Then it uses that model to predict the missing data values. Hot deck imputation,
originally developed for the Income Supplement of the Current Population Survey
utilizes matching based on observed covariates in order to replace an observation
with missing data values with values from observations without missing data.
Alternatively, one can use methods such as inverse probability weighting of com-
plete cases by probability of being observed in order to account of missing data. The
procedure is defined in detail in Chapters 1 & 2. A natural approach to dealing
with missing data under a dynamic treatment regime setting is to use this approach,
called inverse probability of treatment weighting (IPTW). Since we had previously
discussed using IPTW to solve the missing data problem of not being on the regime
of interest it is a natural course to use the same for drop out. The primary advantage
of IPTW in a dynamic treatment regime setting as shown described by Bembom and
van der Laan [2006] is that it allows for unbiased estimation of the outcome under
a regime without having to know or specify the distribution of either the intermedi-
ate response or outcome. Defining an Inverse Probability of Treatment and Missing
estimator is the first step toward presenting doubly robust or efficient estimators in
a manner that takes missing data due to drop-out into account.
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In this chapter we discuss causal inference in a dynamic treatment regime set-
ting with data missing at random and more specifically, we describe two two IPTW
estimators using different methods for estimating second stage treatment probabil-
ity and derive the variance of these estimators. A simulation study then follows to
compare all the discussed estimators in a multiplicity of conditions with other com-
peting estimators. We then present a data analysis of the STAR*D clinical study in
which we apply our estimator of interest to estimate the effects of two stage dynamic
treatment regimes in the presence of missing data. Lastly, we will summarize the
results in this chapter in a discussion section.
3.2 NOTATION
Consider the two-stage randomized trial considered in Chapter 2 where participants
are assigned to a first stage treatment, with responders to that treatment being
moved to follow-up and non-responders moved to a second stage of treatment. We
will use similar notation as we did in Chapter 2, however we describe that again in
detail here. For i = 1, ..., n let Z
(A)
ji be the indicator for the i
th patient receiving first
stage treatment Aj, Z
(A)
ji = 1, if the patient receives Aj, 0, otherwise. Let Ri denote
the indicator of whether participant i responds to the initial treatment. Conditional
on not responding to the first stage treatment, let Z
(B)
ki be the indicator for the i
th
patient receiving second stage treatment Bk, Z
(B)
ki = 1, if the patient receives Bk, 0,
otherwise. The observed data from the ith participant for this trial in the presence
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of missing data can be written as
Oi = [X
∗
1i, {Z(A)ji , j = 1, 2},∆(1)i ,∆(1)i {Ri, X∗2i, (1−Ri)Z(B)ki (k = 1, 2),∆(2)i ,∆(2)i Yi}]
(3.1)
for i = 1, ..., n, where X∗1i and X
∗
2i are potential covariates prior to the random-
ization at stages 1 and 2, ∆
(1)
i = 1 if the participant completed the first stage of
treatment and stayed in the study until the second stage, 0 otherwise. ∆
(2)
i = 1
if the participant’s outcome Yi was observed after responding to the first stage of
treatment and being moved to follow-up or receiving a second stage of treatment
after not responding to the first stage of treatment, 0 otherwise.
At each stage we observe covariate information, the ith patient’s observed co-
variate information for the first and second stages of treatment is X∗1i and X
∗
2i.
Combined with the treatment assignments themselves we define X1i = (X
∗T
1i , Z
(A)
ji )
T
and X2i = (X
∗T
2i , RiZ
(B)
ki )
T as the observed data at stages 1 and 2. Define the ith
patient’s outcome as Yi.
For missing data define ∆
(1)
i and ∆
(2)
i as the i
th patient’s indicators for not being
missing at the first and second stages of treatment respectively. We define pi
(1)
i =
Pr(∆
(1)
i = 1) and pi
(2)
i = Pr(∆
(2)
i = 1). It is seldom that these probabilities are
inherently known in missing data problems. Based on the observed data at each
stage we define the modeled probabilities of not being missing at each stage as
pi(1)(X1i, β1) and pi
(2)(X2i, β2), where β1 and β2 are the coefficients describing the
relationship between the outcome and X1i and X2i respectively with a logit link.
Our goal is to estimate µ[d(Aj, Bk)] = E{Y [d(Aj, Bk)]}, the mean of a population
who were treated with d(Aj, Bk). The regime ’Treat with Aj, if non-response treat
with Bk’. For brevity’s sake we will refer to µ[d(Aj, Bk)] from now on as simply µ.
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3.3 CAUSAL INFERENCE FOR DYNAMIC TREATMENT
REGIMES WITH DATA MISSING AT RANDOM
Consider a single stage scenario, the interest is to estimate the mean of an outcome
Y, µ = E[Y |A1] based on a sample of participants receiving A1 and other treatments.
The Inverse Probability of Treatment Weighted Estimator of µ is given by
µˆIPTW =
1
n
n∑
i=1
Z
(A)
i
pi(A)
Yi , (3.2)
where Z
(A)
i is the indicator for receiving the treatment of interest in this one
stage setting and pi(A) is the corresponding probability of receiving that treatment.
This IPTW estimator solves the missing data problem of not observing the coun-
terfactual outcome under the treatment of interest due to a portion of the sample
receiving a treatment other than A1. We can expand this missing data problem to
include missing data due to dropout. Suppose that in addition to having patients
whose outcome under A1 is not observed due to receiving A2, we also have patients
drop out of the study after randomization and thus have missing outcome data.
Consider the modified IPTW estimator
µˆIPTMW =
1
n
n∑
i=1
∂iZ
(A)
i
Pr(∆
(1)
i = 1|Xi, Z(A)i )
Yi , (3.3)
where ∂i indicates if the data are observed or not, Pr(∆
(1)
i = 1|Xi, Z(A)i ) is the
probability that the data is observed given the covariates Xi and Z
(A)
i andˆindicates
that this probability is estimated from the data. Now we have an estimator that
utilizes weighting to solve two different missing data problems, that of not being on
the treatment of interest as well as that of dropout.
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When Pr(∆
(1)
i = 1|Xi, Z(A)i ) is known we can see that µˆIPTMW is an unbiased
estimator of µ = E[Y |A1]
E[µˆIPTMW ] = E
[
1
n
n∑
i=1
∂iZ
(A)
i Yi
pi(A)Pr(∆
(1)
i = 1|Xi, Z(A)i )
]
= E
[
∂iZ
(A)
i Yi
pi(A)Pr(∆
(1)
i = 1|Xi, Z(A)i )
]
= E
[
E
[
∂iZ
(A)
i Yi
pi(A)Pr(∆
(1)
i = 1|Xi, Z(A)i )
∣∣∣∣∣Z(A)i , Xi
]]
= E
[
Z
(A)
i
pi(A)Pr(∆
(1)
i = 1|Xi, Z(A)i )
E
[
∂iYi
∣∣∣∣∣Z(A)i , Xi
]]
= E
[
E[∂i|Xi, Z(A)i ]pi(A)
pi(A)Pr(∆
(1)
i = 1|Xi, Z(A)i )
E
[
Yi
∣∣∣∣∣Z(A)i = 1, Xi
]]
= E[Y |Aj] .
(3.4)
Moving into a two stage dynamic treatment regime setting these exist for a variety
of estimators for estimating mean outcome under a specific regime.
For complete data, Bembom and van der Laan [2006] describes a method, known
as g-computation, originally described by Robins [1986], that uses weighted aver-
ages, based on response probability, of conditional intermediate responses to achieve
unbiased estimates of mean regime outcomes. Specifically, the mean outcome under
regime d(Aj, Bk) is estimated as
µˆG[d(Aj, Bk)] =
1
n
n∑
i=1
{
Rimj(X
∗
1i, X
∗
2i) + (1−Ri)mjk(X∗1i, X∗2i)
}
, (3.5)
where mj(X
∗
1i, X
∗
2i) and mjk(X
∗
1i, X
∗
2i) respectively are the estimated mean out-
come for responders receivingAj on initial treatment and the same for non-responders
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on treatment path Aj → Bk. These can be estimated from the observed data. When
the pathway means are correctly specified this estimator has very low bias and is ex-
tremely efficient. In the presence of missing data these quantities can be estimated
using only complete cases but these may be biased estimates, which may cause the
estimator itself to be biased.
When there are no missing data the Inverse Probability of Treatment Weighted
estimator in a two stage dynamic treatment regime setting is described by Wahed
and Tsiatis [2004] is
µˆIPTW [d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji
pi
(A)
j
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
Yi . (3.6)
Note that, following our previous arguments, under the assumption of consis-
tency, this estimator is an unbiased estimator of µ[d(Aj, Bk)] when pi
(A)
j and pi
(B)
jk are
known. We expand our IPTW estimator to include weights for missing via dropout.
However, unlike the previous single stage estimator, there is now dropout during two
different levels of treatment. This yields four different levels of missing data for the
outcome under the regime of interest. First is for patients who receive a first level
treatment other than that of interest, second is for patients who dropout during the
first stage, third for patients who receive a second level treatment other than that of
interest, and finally, for those that dropout during the second level of treatment or
during follow-up after responding to the first level of treatment. This leads to the
natural IPTW estimator
µˆIPTMW [d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pˆi
(A)
j pi
(1)(X1i, βˆ1)pi(2)(X2i, βˆ2)
[
Ri +
(1−Ri)Z(B)ki
pˆi
(B)
jk
] }
Yi ,
(3.7)
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where the hats indicate that pi(1)(X1i, βˆ1) and pi
(2)(X2i, βˆ2) are modeled estima-
tors of pi
(1)
i and pi
(2)
i respectively based on the data prior to the missing. These
models utilize logistic regression to express treatment probability as a function of
the observed covariates. It is important to note that pi(2)(X2i, βˆ2) is calculated from
only those for who ∆
(1)
i = 1. Likewise, pˆi
(B)
jk and pˆi
(B)
jk are estimates of pi
(B)
jk and
pi
(B)
jk respectively, calculated as the mean treatment assignments at each level for the
observed data.
This is our Inverse Probability of Treatment and Missing Weighted estimator and
it will be the focus of this chapter.
3.4 VARIANCE OF THE IPTMW ESTIMATOR
3.4.1 When pi
(B)
jk is estimated using Complete Cases
The Inverse Probability of Treatment and Missing Weighted estimator described in
the previous section is given by
µˆIPTMW [d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pˆi
(A)
j pi
(1)(X1i, βˆ1)pi(2)(X2i, βˆ2)
[
Ri +
(1−Ri)Z(B)ki
pˆi
(B)
jk
] }
Yi ,
(3.8)
where βˆ1 and βˆ2 are estimated via logistic regression of ∆
(1)
i and ∆
(2)
i on the
covariates observed prior to patients dropout. In other words βˆ1 and βˆ2 are solutions
of the equations
0 =
n∑
i=1
X1i
(
∆
(1)
i −
1
1 + e−XT1iβ1
)
(3.9)
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and
0 =
n∑
i=1
∆
(1)
i
pi(1)(X1i, β1)
X2i
(
∆
(2)
i −
1
1 + e−XT2iβ2
)
. (3.10)
In this situation, pˆi
(A)
j and pˆi
(B)
jk are estimated using the empirical average of
participants receiving Aj and Bk after Aj respectively. In other words
pˆi
(A)
j =
1
n
n∑
i=1
Z
(A)
ji (3.11)
and
pˆi
(B)
jk =
∑n
i=1 ∆
(1)
i ∆
(2)
i Z
(A)
ji Z
(B)
ki∑n
i=1 ∆
(1)
i ∆
(2)
i Z
(A)
ji
. (3.12)
Putting these all together, we can express the IPTMW estimator as a solution
of µ to the estimating equations
n∑
i=1
ψi(Oi; θˆ) =

ψiA(Z
(A)
ji ; pˆi
(A)
j )
ψi1(X1i,∆
(1)
i ; βˆ1)
ψiB(Z
(B)
ki , X1i,∆
(1)
i ; pˆi
(B)
jk )
ψi2(X2i,∆
(1)
i ,∆
(2)
i ; βˆ1, βˆ2)
ψiµ(Oi; µˆ)

= 0 (3.13)
where
θ = (pi
(A)
j , β1, pi
(B)
jk , β2, µ) . (3.14)
aˆindicates a solution, and the individual ψ functions are the estimating equations
corresponding to all the estimated parameters in the estimator µˆ along with the
estimate of µ itself. More specifically,
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ψiA(Z
(A)
ji ; pi
(A)
j ) = Z
(A)
ji − pi(A)j
ψi1(X1i,∆
(1)
i ; β1) = X1i
(
∆
(1)
i −
1
1 + e−XT1iβ1
)
ψiB(Z
(B)
ki , X1i,∆
(1)
i ; pˆi
(B)
jk ) = Z
(A)
ji (1−Ri)∆(1)i (Z(B)ki − pi(B)jk )
ψi2(X2i,∆
(1)
i ,∆
(2)
i ; β1, β2) =
∆
(1)
i
pi(1)(X1i,β1)
X2i
(
∆
(2)
i −
1
1 + e−XT2iβ2
)
ψiµ(Oi;µ) =
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pi
(A)
j pi
(1)(X1i,β1)pi(2)(X2i,β2)
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
]}
Yi − µ .
By defining the above estimator as a solution to a set of estimating equations we
are able to classify it as an M-Estimator. It follows then that it is asymptotically
normal, as well as consistent (Stefanski and Boos [2002]) as long as the estimating
equations are correctly specified. We can therefore use the sandwich estimator, Vn,
to obtain an estimate of its asymptotic variance, namely
Vn = An(θˆ)
−1Bn(θˆ){An(θˆ)−1}T/n , (3.15)
where
An(θ) = − 1
n
n∑
i=1
∂ψi(θ)
∂θ
, (3.16)
and
Bn(θ) =
1
n
n∑
i=1
ψi(θ)ψi(θ)
T . (3.17)
More explicitly, the An(θ) can be written as
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An(θ) =
1
n
n∑
i=1
−∂ψi(θ)
∂θ
=
1
n
n∑
i=1

−1 0 0 0 0
0 −∂ψi1
∂β1
0 0 0
0 0 −Z(A)ji (1−Ri)∆(1)i 0 0
0 −∂ψi2
∂β1
0 −∂ψi2
∂β2
0
− ∂ψiµ
∂pi
(A)
j
−∂ψiµ
∂β1
− ∂ψiµ
∂pi
(B)
jk
−∂ψiµ
∂β2
−1

where the derivative elements in the A matrix are as follows
∂ψi1
∂β1
= −pi(1)(X1i, β1)(1− pi(1)(X1i, β1))X1iXT1i
∂ψi2
∂β1
= −(∆(2)i − pi(2)(X2i, β2))X2iXT1i
(
1
pi(1)(X1i, β1)
− 1
)
∆
(1)
i
∂ψi2
∂β2
= −pi(2)(X2i, β2)(1− pi(2)(X2i, β2))X2iXT2i
∆
(1)
i
pi(1)(X1i, β1)
∂ψiµ
∂pi
(A)
j
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
(pi
(A)
j )
2pi(1)(X1i, β1)pi(2)(X2i, β2)
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
Yi
∂ψiµ
∂β1
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pi
(A)
j pi
(2)(X2i, β2)
(
1
pi(1)(X1i, β1)
− 1
) [
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
XT1iYi
∂ψiµ
∂pi
(B)
jk
= −
{
Z
(A)
ji (1−Ri)Z(B)ki ∆(1)i ∆(2)i
pi
(A)
j (pi
(B)
jk )
2pi(1)(X1i, β1)pi(2)(X2i, β2)
}
Yi
∂ψiµ
∂β2
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i X2i
pi
(A)
j pi
(1)(X1i, β1)
(
1
pi(2)(X2i, β2)
− 1
) [
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
XT2iYi
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3.4.2 Using A Weighted Estimate Of pi
(B)
jk
Previously we estimate pi
(B)
jk as the mean second stage treatment assignment using the
observed data. However, this process of estimating pi
(B)
jk does not take into account
patients who dropout out in the first stage. In order to recover information from
patients who dropped out during the first stage, let us define a new estimator of pi
(B)
jk ,
pˆi
(B)
jk =
∑n
i=1
Z
(A)
ji (1−Ri)∂1Z(B)ki
pi(1)(X1i,βˆ1)∑n
i=1
Z
(A)
ji (1−Ri)∂1
pi(1)(X1i,βˆ1)
. (3.18)
This estimator uses inverse probability weighting to account for patients whose
second stage treatment assignment was never seen due to dropout. The Inverse
Probability of Treatment and Missing Weighted estimator has not changed from
(3.8) except that now pi
(B)
jk is estimated via (3.18) instead of (3.12). We will refer to
this estimator as IPTMW2.
Similarly to in the previous section we can express the IPTMW with a weighted
estimate of pi
(B)
jk as the solution to
n∑
i=1
ψi(Oi; θˆ) =

ψiA(Z
(A)
ji ; pˆi
(A)
j )
ψi1(X1i,∆
(1)
i ; βˆ1)
ψiB(Z
(B)
ki ; βˆ1, pˆi
(B)
jk )
ψi2(X2i,∆
(1)
i ,∆
(2)
i ; βˆ1, βˆ2)
ψiµ(Oi; µˆ)

= 0 (3.19)
where
Oi = (X
∗
1i, X
∗
2i,∆
(1)
i ,∆
(2)
i , Z
(A)
ji ,∆
(1)
i (1−Ri)Z(B)ki ,∆(1)i Ri, Yi) and θ = (pi(A)j , β1, β2, piB, µ) .
(3.20)
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Once again these equations are the estimating equations corresponding to all the
estimated parameters in the estimator along with the estimate itself. The equations
ψiA, ψi1, ψi2, ψiµ are as described before, and
ψiB(Z
(B)
ki ; β1, pi
(B)
jk ) =
Z
(A)
ji (1−Ri)∆(1)i
pi(1)(X1i,β1)
(Z
(B)
ki − pi(B)jk )
By defining the above estimator as a solution to a set of estimating equations
we are once again able to classify it as an M-Estimator. It follows then that it is
asymptotically normal, as well as consistent (Stefanski and Boos [2002]) as long as
the estimating equations are correctly specified. We can therefore use the sandwich
estimator, Vn, to obtain an estimate of its variance.
Vn = An(θˆ)
−1Bn(θˆ){An(θˆ)−1}T/n , (3.21)
where
An(θ) = − 1
n
n∑
i=1
∂ψi(θ)
∂θ
, (3.22)
and
Bn(θ) =
1
n
n∑
i=1
ψi(θ)ψi(θ)
T . (3.23)
Now the An(θ) becomes
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An(θ) =
1
n
n∑
i=1
−∂ψi(θ)
∂θ
=
1
n
n∑
i=1

−1 0 0 0 0
0 −∂ψi1
∂β1
0 0 0
0 −∂ψiB
∂β1
−Z(A)ji (1−Ri)∆(1)i
pi
(1)
i
0 0
0 −∂ψi2
∂β1
0 −∂ψi2
∂β2
0
− ∂ψiµ
∂pi
(A)
j
−∂ψiµ
∂β1
− ∂ψiµ
∂pi
(B)
jk
−∂ψiµ
∂β2
−1

where the derivative elements in the A matrix are as follows
∂ψi1
∂β1
= −pi(1)(X1i, β1)(1− pi(1)(X1i, β1))X1iXT1i
∂ψiB
∂β1
= −Z(A)ji (1−Ri)∆(1)i XT1i
(
1
pi
(1)
i
− 1
)
(Z
(B)
ki − pi(B)jk )
∂ψi2
∂β1
= −(∆(2)i − pi(2)(X2i, β2))X2iXT1i
(
1
pi(1)(X1i, β1)
− 1
)
∆
(1)
i
∂ψi2
∂β2
= −pi(2)(X2i, β2)(1− pi(2)(X2i, β2))X2iXT2i
∆
(1)
i
pi(1)(X1i, β1)
∂ψiµ
∂pi
(A)
j
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
(pi
(A)
j )
2pi(1)(X1i, β1)pi(2)(X2i, β2)
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
Yi
∂ψiµ
∂β1
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pi
(A)
j pi
(2)(X2i, β2)
(
1
pi(1)(X1i, β1)
− 1
) [
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
XT1iYi
∂ψiµ
∂pi
(B)
jk
= −
{
Z
(A)
ji (1−Ri)Z(B)ki ∆(1)i ∆(2)i
pi
(A)
j (pi
(B)
jk )
2pi(1)(X1i, β1)pi(2)(X2i, β2)
}
Yi
∂ψiµ
∂β2
= −
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i X2i
pi
(A)
j pi
(1)(X1i, β1)
(
1
pi(2)(X2i, β2)
− 1
) [
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk
] }
XT2iYi
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A notable difference between this variance estimator and the variance estimator
for IPTMW using the complete case estimator of pi
(B)
jk is
∂ψB
∂β1
, which is now non-zero.
3.5 SIMULATION
We based our simulation on Kang and Schafer (2007) with a few notable exceptions.
We assume a two stage design, with non-responders from the first stage being re-
randomized in the second stage. In this simulation we concerned ourselves with the
estimation of the mean counterfactual outcome µ{Y [d(A1, B1)]} = E{Y [d(A1, B1)]},
the mean outcome for the patient population had everyone been on the regime
d(A1, B1). The indicators for A1 and B2, Z
(A)
1 and Z
(B)
2 were generated from a
Bernoulli distribution with pi
(A)
1 = pi
(B)
11 = 0.5. Let Z
(A)
2 = 1 − Z(A)1 and Z(B)2 =
1− Z(B)1 . Intermediate response, Ri was generated as
R ∼ BERNOULLI(piR), (3.24)
where piR = τ0 + τ1 ∗Z(A)1 , j = 1, 2. We consider various combinations of τ0 and τ1 to
produce varying response rates. For example, (τ0, τ1) = (0.2, 0.25) produces a 45%
response rate among patients who receive treatment A1.
The outcome variable, Y , is then generated as
Y = γ0 + γ1 ∗ Z(A)1 + γ2 ∗ Z(B)1 ∗R + γ3 ∗R + γ4 ∗Xa + γ5Xb + e , (3.25)
where Xa, Xb, and e are independent random variables generated from a standard
normal distribution [N(0, 1)] and γ = (γ0, γ1, γ2, γ3, γ4, γ5) are varied to produce
different relationships between the treatments, covariates, and outcomes. For γ =
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(7, 3, 2, 1, 5.5, 5.4), the true value of the estimand, the mean counterfactual outcome
µ{Y [d(A1, B1)]} = E{Y [d(A1, B1)]} was calculated to be was 11.35.
The probability of being observed in the first stage was specified as
pi(1)(X1i, β1) = expit(β10 + β11 ∗Xa + β12 ∗ Z(A)1 ) , (3.26)
and ∆
(1)
i is then drawn from a Bernoulli distribution with probability pi
(1)(X1i, β1).
Parameters (β10, β11, β12) were varied to change the properties of missing data in
the simulation; β11 is related to the strength of the association between missing
data generation, probability of treatment assignment, and outcome, β12 controls
the relative rate of missing data in the two groups, while β10 controls the amount
of missing data which was varied to achieve between 10% and 50% of data being
missing.
In the second stage the probability of being observed is defined as
pi(2) = expit(β20 + β21 ∗Xb + β22 ∗ Z(A)j + β23 ∗ Z(B)k ) (3.27)
where β20 was also varied to achieve a range of missing data between 10% and 50%.
The values of β10, β11, and β20 along with the percentage of observations missing
outcome data can be seen in Table 12. We performed a series of 5000 Monte Carlo
simulations in order to asses the validity of our estimator under various levels of
dropout and association between missing data generation, probability of treatment
assignment, and outcome. We also varied sample size, running the simulation at
n = 500 and n = 2000.
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Table 12: Levels of Missing Data for varying β11 and β10 and β20
β11 β10 β20 Missing (%)
-.75 0.5 0.5 12%
-.75 1.5 1.5 26%
-.75 2.5 2.5 51%
-2.75 1 0.5 19%
-2.75 2 1.5 32%
-2.75 3 2.5 52%
β11 = −.75 corresponds to a strong association between probability of being missing, treatment
assignment, and outcome and β11 = −2.75 corresponds to a weak one. (β12, β21, β22, β23) were fixed
at (1.2, 0.4, -0.2, 1.3).
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3.5.1 Simulation Results
In Table 13 we see the results of the simulation at n = 500 for 9% of observa-
tions missing for patients on the regime of interest and a strong association between
probability of being missing, treatment assignment, and outcome. The Inverse Prob-
ability of Missing Weighted estimators have smaller relative bias (0.04% with com-
plete case estimates of second stage treatment probability, IPTMW1, and 0.16%
with the weighted estimate, IPTMW2) than both the complete case CC-G-Comp
estimator, CC-G-Comp, (8.58%) and the complete case Inverse Probability of Treat-
ment Weighted estimator, CC-IPTW, (15.1%). The Monte Carlo standard errors
were smallest for the CC-G-Comp estimator (0.61) followed by IPTMW1 (0.77),
CC-IPTW (0.81) and IPTMW2 (0.86). However, the composite metric of the MSE
is smaller for the IPTMW estimators (1.20 and 1.48) than for both CC-IPTW (4.26)
and the CC-G-Comp estimator (1.69). The standard errors obtained with bootstrap-
ping largely echoed the Monte Carlo standard errors, more closely for CC-G-Comp
(0.61 vs 0.61) and CC-IPTW (.81 vs .80) than for the IPTMW estimators (0.77
and 0.73 vs 0.86 and 0.79). Coverage probabilities for 95% confidence intervals con-
structed using the bootstrap standard errors yield better coverage for the IPTMW
estimators (0.98% and 0.97%) than for CC-G-Comp (0.83%) and CC-IPTW (0.52%).
This is more likely due to the large bias for the CC-G-Comp and CC-IPTW esti-
mates.
Table 13 also shows that as the percentage of missing data increases (when there
is a strong association between probability of being missing, treatment assignment,
and outcome) that the IPTMW estimators continue to perform well across all metrics
while CC-G-Comp and CC-IPTW tend to be more biased and inefficient. This is
most obvious in their relative biases, which yield poor results at 32% of data missing
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(13.9% and 25.5%) and abysmal results at 52% of data missing (21.5% and 41.8%).
The coverage of 95% confidence intervals for CC-G-Comp and CC-IPTW at even
moderate levels of missing data tell a similar story (50.0% and 13.7% coverage at
32% missing data).
The Table also shows the results at n=500 when there is only a weak association
between missing data generation, probability of treatment assignment, and outcome.
A notable finding is that CC-G-Comp yields good results at low and moderate levels
of missing. At 26% missing data CC-G-Comp is only visibly worse then the IPTMW
estimators in terms of relative bias (4.65% vs -0.10% and -0.06%), is almost similar
in terms of coverage (94.4% vs 97.9% and 97.8%) and MSE (1.13 vs 1.04 and 1.12),
and has a superior MCSE (0.65 vs 0.72 and 0.75).
Another interesting phenomenon is that across levels of missing data IPTMW1
has a higher relative bias than IPTMW2: at 12% missing data -0.07% vs -0.06%, at
26% missing data -0.10% vs -0.06%, and at 51% missing data -0.07% vs -0.04%.
All of these results are mirrored in Table 13 where the sample size is increased to
n=2000 except that the variances and MSEs are lower because of the larger sample
sizes.
In Table 15 we see how the estimate of the standard error obtained from the
sandwich estimator of the variance compares to the Monte Carlo standard error at
n=500 for when there are different levels association between missing data generation,
probability of treatment assignment, and outcome. From the results in that Table
we see that the estimates of the standard errors are more accurate when there is a
weak association. These results are investigated for the larger sample size of n=2000,
which can be seen in Table 16.
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Table 13: n=500, Simulation results for estimating µ{Y [d(A,B)]} = 11.356
Strength of (%) Method Bias MCSE MSE Bootstrap Coverage
Association Drop-Out (%) SE (%)
Strong 19% CC −G− Comp 8.58 0.61 1.69 0.61 83
CC − IPTW 15.10 0.81 4.26 0.80 52
IPTMW1 0.04 0.77 1.20 0.73 98
IPTMW2 0.16 0.86 1.48 0.80 97
32% G− Comp 13.90 0.64 3.30 0.64 50
IPTW 25.50 0.95 10.18 0.95 14
IPTMW 0.05 0.85 1.45 0.79 97
IPTMW2 0.28 1.07 2.28 0.90 96
52% G− Comp 21.50 0.72 6.98 0.71 14
IPTW 41.80 1.28 25.84 1.28 01
IPTMW 0.23 1.02 2.08 0.93 95
IPTMW2 0.71 1.31 3.45 1.08 94
Weak 12% G− Comp 1.85 0.62 0.80 0.62 98
IPTW 6.65 0.76 1.73 0.76 90
IPTMW -0.07 0.69 0.96 0.69 98
IPTMW2 -0.06 0.70 0.98 0.70 98
26% G− Comp 4.65 0.65 1.13 0.65 94
IPTW 16.10 0.90 4.98 0.91 52
IPTMW -0.10 0.72 1.04 0.72 98
IPTMW2 -0.06 0.75 1.12 0.75 98
51% G− Comp 10.20 0.73 2.41 0.73 76
IPTW 35.40 1.23 19.11 1.26 06
IPTMW -0.07 0.80 1.27 0.80 97
IPTMW2 0.04 0.85 1.46 0.86 97
CC −G−Comp = Complete G-Computation, CC − IPTW = Complete Case Inverse Probability
of Treatment Weighted Estimator, IPTMW1 = Inverse Probability of Missing Weighted Estima-
tor with complete case estimator of pi
(B)
jk , IPTMW2 = Inverse Probability of Missing Weighted
Estimator with weighted estimate of pi
(B)
jk
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Table 14: n=2000, Simulation results for estimating µ{Y [d(A,B)]} = 11.356
Strength of (%) Method Bias MCSE MSE Bootstrap Coverage
Association Drop-Out (%) SE (%)
Strong 19% G− Comp 8.69 0.31 1.16 0.305 63
IPTW 15.10 0.40 3.27 0.40 11
IPTMW -0.002 0.37 0.28 0.37 99.9
IPTMW2 0.06 0.47 0.44 0.41 99.7
32% G− Comp 14.00 0.32 2.73 0.32 6
IPTW 25.50 0.47 8.83 0.47 <0.1
IPTMW 0.05 0.42 0.35 0.40 99.9
IPTMW2 0.18 0.55 0.60 0.48 99.4
51% G− Comp 21.50 0.36 6.20 0.36 <0.1
IPTW 41.60 0.63 23.10 0.64 <0.1
IPTMW 0.09 0.53 0.57 0.49 99.6
IPTMW2 0.28 0.69 0.96 0.59 98.8
Weak 11% G− Comp 1.97 0.31 0.24 0.31 99.7
IPTW 6.68 0.38 0.87 0.38 88
IPTMW -0.03 0.35 0.24 0.35 100
IPTMW2 -0.03 0.35 0.25 0.35 99.9
26% G− Comp 4.79 0.33 0.51 0.33 95
IPTW 16.20 0.45 3.79 0.45 12
IPTMW -0.02 0.36 0.27 0.36 100
IPTMW2 -0.01 0.38 0.28 0.37 99.9
51% G− Comp 10.20 0.37 1.63 0.37 52
IPTW 35.30 0.62 16.79 0.62 <0.1
IPTMW -0.01 0.40 0.32 0.40 99.8
IPTMW2 0.01 0.43 0.37 0.43 99.7
CC −G−Comp = Complete G-Computation, CC − IPTW = Complete Case Inverse Probability
of Treatment Weighted Estimator, IPTMW1 = Inverse Probability of Missing Weighted Estima-
tor with complete case estimator of pi
(B)
jk , IPTMW2 = Inverse Probability of Missing Weighted
Estimator with weighted estimate of pi
(B)
jk
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Table 15: n=500, µ{Y [d(A,B)]} = 11.356
Association Level of Level of Method Sandwich MCSE Coverage
Missing Data Missing Data Est. SE (%)
Overall On Regime
Strong 19% 19% IPTMW1 0.774 0.722 95.1
IPTMW2 0.859 0.776 94.9
32% 31% IPTMW1 0.853 0.797 95.3
IPTMW2 1.070 0.883 95.1
52% 48% IPTMW1 1.020 0.967 95.9
IPTMW2 1.310 1.070 95.1
Weak 12% 8% IPTMW1 0.691 0.691 95.3
IPTMW2 0.701 0.701 95.2
26% 19% IPTMW1 0.722 0.725 94.9
IPTMW2 0.747 0.749 95.1
51% 40% IPTMW1 0.797 0.817 95.1
IPTMW2 0.854 0.869 95.2
IPTMW1 = Inverse Probability of Missing Weighted Estimator with complete case estimator of
pi
(B)
jk , IPTMW2 = Inverse Probability of Missing Weighted Estimator with weighted estimate of
pi
(B)
jk
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Table 16: n=2000, µ{Y [d(A,B)]} = 11.356
Association Level of Level of Method Sandwich MCSE Coverage
Missing Data Missing Data Est. SE (%)
Overall On Regime
Strong 19% 19% IPTMW1 0.372 0.369 95.0
IPTMW2 0.471 0.410 94.9
32% 28% IPTMW1 0.421 0.417 95.8
IPTMW2 0.548 0.478 95.1
52% 47% IPTMW1 0.534 0.539 96.8
IPTMW2 0.693 0.615 95.8
Weak 11% 9% IPTMW1 0.348 0.346 95.0
IPTMW2 0.353 0.351 95.1
26% 20% IPTMW1 0.364 0.362 95.0
IPTMW2 0.377 0.374 95.0
51% 41% IPTMW1 0.403 0.409 95.2
IPTMW2 0.430 0.434 95.2
IPTMW1 = Inverse Probability of Missing Weighted Estimator with complete case estimator of
pi
(B)
jk , IPTMW2 = Inverse Probability of Missing Weighted Estimator with weighted estimate of
pi
(B)
jk
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3.6 CONCLUSION
For a strong association between probability of being missing, treatment assignment,
and outcome the IPTMW estimators are less biased, have a better MSE, and better
coverage probabilities then both CC-IPTW and CC-G-Comp. As the level of missing
data increases the IPTW and G-Computation estimators become inefficient and more
biased than the IPTMW estimators.
For a weak association between probability of being missing, treatment assign-
ment, and outcome at both sample sizes CC-G-Comp is competitive with both
IPTMW estimators and even has a noticeably lower MCSE and MSE with low levels
of missing data.
Across all levels of missing data the estimator of the variance of the IPTMW
estimators is more accurate when there is a weak association between probability of
being missing, treatment assignment, and outcome as opposed to a strong one. This
may be caused by the increased variability of dropout in the first stage that exists
as a result of manner in which we strengthen the association between probability of
being missing, treatment assignment, and outcome in our simulation.
3.7 ANALYSIS OF STAR*D DATA
The Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, Trial
was a multistage trial designed to test different regimes of depression treatments.
The trial contained 4,041 patients between the ages of 18 and 75 who had received
a clinical diagnosis of nonpsychotic major depressive disorder under the DSM-IV
checklist. A patient that is considered to respond to treatment will continue taking
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that treatment, while those that do not respond are re-randomized to a treatment
within a treatment-grouping of their own choice.
The trial was designed with 4 (and a half) stages. This study contains a unique
element called equipoise stratified randomization, meaning that patients were given
the option of selecting classes of treatments that they would find acceptable to be
on and then were randomized to one of the treatments within those groups. This
was done in order to boost compliance and decrease drop-out. A patient with more
control over their treatment is thought to be more inclined to follow that treatment
and not leave the study. Everyone received the same treatment in the first stage,
an SSRI called citalopram. Non-responders at each stage were offered a choice of
switching off of their current medication or supplementing it with another treatment.
Non-responders to the second stage treatment who received cognitive therapy or
citalopram supplemented with cognitive therapy that stage were randomized to one
of two medicinal treatments at what investigators called stage 2A. The purpose of
this was to make sure everyone that made it to the third stage received a follow up
medication to citalopram. In the STAR*D Trial responders to third stage treatment
are kept on their treatment while non-responders receive a fourth stage of treatment.
However, as previously stated our analysis stops after the third stage. A visual
representation of the trial can be seen in figure 4
Response between stages was defined as either a 50% reduction in QIDS-16 (Quick
Inventory of Depressive Symptomatology) self reported score, or a QIDS-16 score
lower than 5, at the end of the stage. The overall outcome of interest for investigators
was the HRSD-17 (Hamilton Rating Scale of Depression) score which was collected
upon study exit.
Although the trial was designed with 4 and a half stages we will only be look-
ing at the 2nd and 3rd stage treatments. This is because everyone received the
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Figure 4: STAR*D Stages of Treatment.
Warden et al. [2007]
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Table 17: STAR*D Dynamic Treatment Regimes
Regime n Mean (QIDS-16) 95% Confidence Interval
d(BUP,MIRT) 96 8.4 ( 8.0 , 8.7 )
d(BUP,NTP) 97 9.1 ( 8.8 , 9.4 )
d(BUP,BUP+LI) 86 9.71 ( 8.8 , 10.5 )
d(BUP,BUP+THY) 76 4.6 ( 3.6 , 5.7 )
d(SER,MIRT) 120 8.9 ( 8.6 , 9.2 )
d(SER,NTP) 109 7.7 ( 7.4 , 8.0 )
d(SER,SER+LI) 98 10.2 ( 9.5 , 10.9 )
d(SER,SER+THY) 97 9.1 ( 8.2 , 9.9 )
d(VEN,MIRT) 121 8.3 ( 8.0 , 8.6 )
d(VEN,NTP) 122 6.4 ( 6.3 , 6.6 )
d(VEN,VEN+LI) 110 7.1 ( 6.6 , 7.7)
d(VEN,VEN+THY) 115 7.1 ( 6.5 , 7.7 )
d(CIT+BUP,MIRT) 160 5.5 ( 5.4, 5.6 )
d(CIT+BUP,NTP) 167 6.2 ( 6.1, 6.4 )
d(CIT+BUP,CIT+LI) 164 7.4 ( 7.0, 7.9 )
d(CIT+BUP,CIT+THY) 170 6.9 ( 6.6 , 7.2 )
d(CIT+BUS,MIRT) 154 5.8 ( 5.7, 5.9 )
d(CIT+BUS,NTP) 162 6.8 ( 6.7 , 7.0 )
d(CIT+BUS,CIT+LI) 146 8.7 ( 8.2 , 9.3 )
d(CIT+BUS,CIT+THY) 153 7.3 ( 7.0 , 7.6 )
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same treatment in the first stage, an SSRI called citalopram, and if we included
the 4th stage into our analysis our regime sample sizes would be too small to make
any reasonable inferences. For the same reason we will also be excluding patients
that received cognitive therapy in the second stage. So our analysis will center on
comparing regimes for follow up medications for patients with depression that are
non-responsive to SSRIs. For that reason stage 2 and 3 treatments will be henceforth
be represented by 1st and 2nd stage notations under methodology developed in this
chapter. So a response to stage 2 would be indicated by R, the indicator for being
observed during stage 3 would be denoted ∆2, and so on.
The QIDS-16 score is the outcome measure of interest in our analysis, rather
than the HRSD-17 (Hamilton Rating Scale of Depression) score used as the primary
outcome for the study. This is because QIDS-16 was recorded at every visit while
HRSD-17 was recorded upon exiting or finishing the trial, QIDS-16 scores would be
available for more patients than the HRSD-17 was for. It should be noted that the
QIDS-16 remission rates were generally higher than HRSD-17 rates, mainly because
the study counted not having an exit HRSD-17 score as non-response. We will also
differ from the study in that we will keep our overall outcome continuous rather than
transform it to being binary. Transforming a continuous measure into a binary one is
always accompanied by a loss of information. For simplicity, we will be taking sample
mean estimates, weighted on probability of being observed, of the probabilities of
treatment.
The probabilities of being observed for each stage were estimated using logistic
regression using variables indicated as being related to dropout by Warden et al.
[2007]. The model for probability of not dropping out in the initial stage of treat-
ment included age and treatment assigned at that stage as covariates. The model for
probability of not dropping out in the second stage of treatment included a binary
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variable for being non-white hispanic, treatment at the prior stage, and treatment as-
signed at that stage. Probability of receiving a particular treatment at each stage was
calculated as it was in the simulation, using the mean of the indicators of treatment
assignment at each stage.
Applying our new, IPTMW estimator with the complete case estimates of second
stage treatment probabilities to the data yields the results seen in the tables and
plots below. Applying the IPTMW2 estimator to the data yielded identical results.
From Table 17 and Figure 5 we can infer that the best induction treatment is switch
to bupropion sustained release and the best follow up treatment is augmenting with
triiodothyronine. The wide confidence interval for d(BUP,BUP+THY ) is the result
of a very small number of patients being on the treatment pathway SER→ SER+
THY . Overall, the analysis indicated the best regime for patients not responding to
citalopram is to augment with bupropion sustained release and if non-response to that
augment instead with triiodothyronine this is contrary to in Chapter 2 that favors
the same regime but augmenting with rather than switching to bupropion sustained
release. Other differences between these results and those presented in Chapter 2 lay
mostly in the size of the confidence intervals and in Chapter 2’s estimates of regime
means are mostly clustered around a QIDS-16 score of 7 while this Chapter has a
larger range of values between scores of 4 and 11.
3.8 DISCUSSION
In this paper we have introduced and discussed estimators that account for partic-
ipant drop-out in two stage dynamic treatment regimes. A new two stage Inverse
Probability of Treatment and Missing Weighted estimator was defined, both utiliz-
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ing a complete case estimate of second stage treatment assignment probability and
an estimate based on weighting observed cases by the inverse of the probability of
being observed during the previous stage. These estimators were compared to com-
plete case estimators typically used to analyze two stage dynamic treatment regimes.
Through these simulations we showed that in a variety of settings these new esti-
mators were superior. Finally, we applied the Inverse Probability of Treatment and
Missing Weighted estimator with a complete case estimate of second stage treatment
assignment probability in order to estimate the treatment effects of different two
stage dynamic treatment regimes for patients with non-psychotic major depressive
disorder who do not respond to SSRIs in the presence of missing data.
In Chapter 3, we discussed the IPTMW estimator when treatment assignment
probabilities were fixed. However, in observational studies, the probability patients
receive a particular treatment is not fixed in advance and hence needs to be estimated
based on patient’s characteristics. Furthermore, following procedures similar to the
one described in Chapter 2, we can augment the IPTMW estimator, to make it
robust to misspecification of the dropout models.
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Figure 5: Forest Plot of STAR*D Dynamic Treatment Regimes
QIDS-16 Score of 5 = Remission; BUP - bupropion sustained release; BUS - buspirone; CIT - citalopram; Li - lithium; MIRT -
mirtazapine; NTP - nortriptyline; SER - sertraline; THY - triiodothyronine
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4.0 AN AUGMENTED INVERSE PROBABILITY OF TREATMENT
AND MISSING WEIGHTED ESTIMATOR FOR TWO-STAGE
DYNAMIC TREATMENT REGIMES
4.1 INTRODUCTION
Observational studies naturally generate data for comparing dynamic treatment
regimes. The sample size, time required, and variety of treatments sometimes make
conducting randomized clinical trials challenging. Then, even when clinical trials are
conducted to study different dynamic treatment regimes they make take on aspects
of observational studies such as non random treatment assignment. One example is
the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, Trial, a
multistage trial designed to test different regimes of depression treatments. In order
to increase patient retention within the trial the investigators employed a technique
called equipoise stratified randomization, where participants would select different
groups of treatment that they found acceptable and then were randomized within
those groups. This was done to give participants more control over the treatments
they received, which in turn was thought to give them more incentive to adhere to
those treatments. Thus the probability of being assigned to a given treatment at
each level was neither known nor random.
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Consider the same two-stage study set-up considered in Chapter 2 where partici-
pants receive a first stage treatment, with responders to that treatment being moved
to follow-up and non-responders receiving a second stage of treatment except that
the treatments are not randomly assigned. For i = 1, ..., n let Z
(A)
ji be the indicator
for the ith patient receiving first stage treatment Aj, Z
(A)
ji = 1, if the patient receives
Aj, 0, otherwise. Let Ri denote the indicator of whether participant i responds to
the initial treatment. Conditional on not responding to the first stage treatment,
let Z
(B)
ki be the indicator for the i
th patient receiving second stage treatment Bk,
Z
(B)
ki = 1, if the patient receives Bk, 0, otherwise. The observed data can be written
as
Oi = [X
∗
1i, {Z(A)ji , j = 1, 2},∆(1)i ,∆(1)i {Ri, X∗2i, (1−Ri)Z(B)ki (k = 1, 2),∆(2)i ,∆(2)i Yi}]
(4.1)
for i = 1, ..., n, where X∗1i and X
∗
2i are potential covariates prior to the random-
ization at stages 1 and 2, ∆
(1)
i = 1 if the participant completed the first stage of
treatment and stayed in the study until the second stage, 0 otherwise. ∆
(2)
i = 1
if the participant’s outcome Yi was observed after responding to the first stage of
treatment and being moved to follow-up or receiving a second stage of treatment
after not responding to the first stage of treatment, 0 otherwise.
At each stage we observe covariate information, the ith patient’s observed co-
variate information for first and second stages of treatment which we define as X∗1i
and X∗2i. Combined with the treatment assignments themselves we define X1i =
(X∗T1i , Z
(A)
ji )
T and X2i = (X
∗T
2i , RiZ
(B)
ki )
T as the observed data prior to treatment
assignment at stages 1 and 2.
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We define pi
(1)
i = Pr(∆
(1)
i = 1) and pi
(2)
i = Pr(∆
(2)
i = 1). It is seldom that
these probabilities are inherently known and we rely on models to estimate them.
The modeled probabilities of not being missing at each stage are pi(1)(X1i, β1) and
pi(2)(X2i, β2), where β1 and β2 are the coefficients describing the relationship between
the outcome and X1i and X2i respectively.
Here the treatment assignment probabilities are not known, let us define them
as pi
(A)
ji = Pr(Z
(A)
ji = 1) and pi
(B)
jki = Pr(Z
(B)
ki = 1|Ri = 1). They are estimated
using logistic regression models that include patient characteristics collected prior to
treatment assignment at each stage.
Our goal is to estimate µ[d(Aj, Bk)] = E{Y [d(Aj, Bk)]}, the mean of a population
who were treated with d(Aj, Bk). The regime ’Treat with Aj, if non-response treat
with Bk. For brevity’s sake we will refer to µ[d(Aj, Bk)] from now on as simply µ.’
In Chapter 3 we defined a two stage Inverse Probability of Treatment and Missing
Weighted (IPTMW) estimator. However, that estimator assumed that probability
treatment assignment at each stage was fixed given prior treatment assignment and
response. So for a two-stage dynamic treatment regime in an observational setting
that experiences missing data problems let us extend the IPTMW to
µˆIPTMW [d(Aj, Bk)] =
1
n
n∑
i=1
{
Z
(A)
ji ∆
(1)
i ∆
(2)
i
pi
(A)
j (X1i, γˆ1)pi
(1)(X1i, βˆ1)pi(2)(X2i, βˆ2)
[
Ri +
(1−Ri)Z(B)ki
pi
(B)
jk (X2i, γˆ2)
] }
Yi ,
(4.2)
where β1 and β2 are parameters associated with the covariates that link them via
the logit function to the indicator for being observed in the first and second stages of
treatment respectively and γ1 and γ2 are perform the same function for the indicators
for first and second stage treatment assignment.
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Defining this Observational Inverse Probability of Treatment and Missing Weighted
estimator is the first step toward moving the estimator introduced in Chapter 3 into
an observational setting. This estimator makes use of patient characteristics to esti-
mate probability of treatment assignment at each stage as opposed to the IPTMW
estimator from Chapter 3 that assumed the probability was fixed across the study
population conditional on prior treatment and response. The next step would be
confirming this estimator is unbiased when the true model parameters are used and
consistent when they are estimated. After that estimation of the variance would
be necessary, likely once again using the sandwich estimator. A simulation would
then check if this estimator performs better than the G-Computation and Inverse
Probability of Treatment Weighted Estimators for observational data in the presence
data missing due to drop-out wile also confirming that the estimator of the variance
is unbiased. Finally this new estimator would be applied to the STAR*D study in
order to utilize data for patients that drop-out while on the regimes of interest while
accounting for the equipoise stratified randomization present in the study.
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